A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: PHASE2
Conditions: Carcinoma, Non-Small-Cell Lung
Sponsor: Celgene

 
 
 
 
 
Protocol Title: A Phase 2 Multicenter, Randomized, 
Placebo Controlled, Double-Blind Study To Assess 
The Safety And Efficacy Of CC-486 (Oral Azacitidine) 
In Combination With Pembrolizumab (Mk-3475) 
Versus Pembrolizumab Plus Placebo In Subjects 
With Previously Treated Locally Advanced Or 
Metastatic Non-Small Cell Lung Cancer 
 
NCT Number:  NCT02546986 
Protocol Amendment 1 Date:  14 December 2015 

',6&/2685(
5('$&7('35272&2/$0(1'0(17
&&16&/
$3+$6(08/7,&(17(55$1'20,=('3/$&(%2&21752//(''28%/(
%/,1'678'<72$66(667+(6$)(7<$1'()),&$&<2)&&25$/
$=$&,7,',1(,1&20%,1$7,21:,7+3(0%52/,=80$%0.9(5686
3(0%52/,=80$%3/863/$&(%2,168%-(&76:,7+35(9,286/<75($7('
/2&$//<$'9$1&('250(7$67$7,&12160$//&(///81*&$1&(5
㻌
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW\RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFDOWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH/DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHUKDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RUUHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV

7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFHUWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HOJHQH¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLSOHV

x
5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQLQJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x
$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGXDOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x
$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLRQDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQIRUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOFRPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\VHV
x
&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFWOLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNVLQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x
,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFWHGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQVSUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVSURWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQH¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODELOLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFDOWULDOVFOLQLFDOWULDOVGDWDVKDULQJ


&(/*(1(35235,(7$5<,1)250$7,21
(
5686
5686
5($7('
5($7('
&$1&(5
&$1&(5
OGQRWEHVKD
OGQRWEHVK
HDUFKHUVDQG
HDUFKHUVDQ
GUHJXO
GUHJXODWLRQ
DWLR
OHJDORUF
JDORUFRQ
RQ
WHGWRFHUWDL
WHGWRFHU
FHUWDLQLQIRU
HUWDLQLQIRU
WHFW&HOJHQH
WHFW&HOJHQ
QJSULQFLSOH
QJSULQFLSOH
JUH\
JUH\ VSDFH
VSDFH
HQWLIL
HQWLILFDWLRQ
FDWL
QWDLQFRQILGH
DLQFRQILG
RQWDLQLGHQ
RQWDLQLGHQ
\DOVRPD\
\DOVRPD\
WKHVLVJHQHU
KHVLVJHQH
HVHDWWDFKPH
HVHDWWDFKP
RG\RIWKHU
RG\RIWKH
O
ERXW&HOJHQ
ERXW&HOJHQ
RIWKDWLQIRU
IWKDWLQIR
LRQDERXWR
LRQDERXWR
PDWLRQDERXW
PDWLRQDERXW
IRXQGDWKWWS
RXQGDWKWWS

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
1
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
TITLE PAGE
A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO 
CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS 
THE SAFETY AND EFFICACY OF CC-486 (ORAL 
AZACITIDINE) IN COMBINATION WITH 
PEMBROLIZUMAB (MK-3475) VERSUS 
PEMBROLIZUMAB PLUS PLACEBO IN SUBJECTS 
WITH PREVIOUSLY TREATED LOCALLY ADVANCED 
OR METASTATIC NON-SMALL CELL LUNG CANCER
PROTOCOL NUMBER:
CC-486-NSCL-001
DATE FINAL:
15 May 2015
DATE AMENDMENT 1 FINAL:
14 Dec 2015
EudraCT NUMBER:
2014-005614-29
IND NUMBER:
123160
SPONSOR NAME / ADDRESS:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
United States
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.
&(/*(1(35
s provided to y
s provided to
staff, and eth
taff, and eth
ent is regarde
ent is regar
may not be di
may not be di
Persons to w
ersons to w
35235,(7$5<,1)250$7,21
CTS 
CTS 
VANCE
VANCE
G CANC
CAN
NSCL
C -001
01
ay
ay 2015
20
4 Dec 2015
Dec 20
2014
2014-00
-0
123
23
35
35
(/
(/
(/
(/
(/
(/
(/

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Name:
Title:
Address: Route de Perreux 1, 
Boudry, Switzerland  2017
Phone:
E-mail:
Note: The back-up 24-hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
Back-up 24-hour Global Emergency Contact Call Center: 
&(/*(1(35235,(7$5<,1)250$7,21
0
50
2
1)
should only
should onl
dical Moni
ical Mon
er: 
5<
$5
$5<

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
3
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
{See appended electronic signature page}
Signature of Celgene Therapeutic Area Head
dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.  
&(/*(1(35235,(7$5<,1
,1
,1)250$7,21
0$
0$
50
content to 
content to
,1

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, International Conference on 
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations 
governing the conduct of clinical studies.
&(/*(1(35235,(7$5<,1)250$7,21
0$
0$
50
s study
s study at m
at
y
, informed 
nformed
ocedures, in
edures, i
national C
nationa
nes, and loc
s, and lo
7$
7$

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
&(/*(1(35235,(7$5<
5<
5<,1)
wi
wi
1)250$7,21
0$
0$
50
th
th
i
ICH G
ICH 
h
ghout the st
out the st
5<

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
PROTOCOL SUMMARY
Study Title
A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety 
and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus 
pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic 
non-small cell lung cancer
Indication  
Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). 
Objectives
Primary Objective:
!
To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo based on progression-free survival (PFS) as measured using Response 
Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Secondary Objectives:
!
To estimate disease control rate (DCR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To estimate overall survival (OS) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To estimate overall response rate (ORR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate safety and tolerability of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486 
Exploratory Objectives:
!
To determine the preliminary efficacy (immune-related [ir] PFS, irDCR, irORR) of 
CC-486 in combination with pembrolizumab versus pembrolizumab plus placebo
based on irRECIST criteria 
!
To explore mechanism and biomarkers associated with efficacy of CC-486 in 
combination with pembrolizumab versus pembrolizumab plus placebo,
Study Design
This is a Phase 2, multicenter, international, randomized, placebo controlled double-blind study 
to assess the safety and efficacy of the combination therapy of CC-486 plus pembrolizumab
versus placebo plus pembrolizumab in previously treated subjects with locally advanced or 
metastatic NSCLC who have received only one prior platinum-based chemotherapy regimen. 
&(/*(1(35235,(7$5<,1)250$7,21
SCLC
SCLC).
us s pembrol
pemb
ured using
red using R
ia
486 pl
6 plus 
us
l
pe
p
486 pl
486 plus
l
p
(ORR)
(ORR) of
of
erabilit
erability of
acebo
eb
mpact of pem
act of pe
mine the pre
ine the p
6 in combin
in combin
d on i
d on irREC
rREC
i
To expl
To explore
ore
combina
combin
Study De
Study D
(/*
(/

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab. A safety analysis will be performed in the first 10 subjects in each 
arm after the completion of at least 1 cycle of treatment.
The randomization will be stratified by histology (non-squamous versus squamous).
An independent Data Monitoring Committee (iDMC) will be established to evaluate safety. 
Following the initial iDMC data review meeting, the iDMC will meet approximately every 6 
months per DMC charter (or more often if requested by the DMC Chairman) to assess safety 
data.  Details are outlined in the DMC charter.
The conduct of this trial will be overseen by a Steering Committee which will serve in an 
advisory capacity to the Sponsor.  
The study will be conducted in compliance with International Conference on Harmonisation 
(ICH) Good Clinical Practices (GCPs).
Study Population
Adult subjects with histologically confirmed diagnosis of locally advanced or metastatic 
NSCLC, lacking or with unknown anaplastic lymphoma kinase (ALK) or epidermal growth 
factor receptor (EGFR) mutations, who have been treated with only 1 prior platinum-based 
chemotherapy regimen for locally advanced or metastatic disease.
Length of Study
Enrollment is expected to take approximately 12 months to complete.  The total length of this 
Phase 2 study with follow-up is estimated to be approximately 2 years. The primary analysis will 
be conducted when 70 PFS events have occurred. 
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol,
whichever is the later date.  
Study Treatments
CC-486/placebo will be administered at a dose of 300 mg orally daily on days 1-14 of a 21-day 
cycle. Pembrolizumab will be administered as a 30-minute intravenous (IV) infusion at a dose of 
200 mg (4 x 50 mg vials) on day 1 of a 21-day cycle. 
Subjects may remain on treatment until radiologic disease progression (for exceptions refer to 
Section 6.4.3), unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of 
consent, subject refusal, physician decision, or death.
Overview of Efficacy Assessments
All subjects will be evaluated for tumor response and progression by Investigator assessment
according to RECIST 1.1 guidelines at screening and every 6 weeks (± 5 days) from 
randomization for the first 24 weeks, and every 9 weeks thereafter until documented disease 
progression (for exceptions refer to Section 6.4.3), start of new anticancer therapy, or withdrawal 
of consent. Subjects will also be evaluated according to irRECIST guidelines in cases of 
progressive disease (PD) per RECIST 1.1.
&(/*(1(35235,(7$5<,1)250$7,21
monisat
onisatioion n
nced 
ced or 
or met
m
K)
K or 
or epi
epide
de
nly 1 prior p
or p
ase
se.
ths to comp
ths to comp
proximately
proximatel
d.
e of the last
e of the last
eceipt of th
eceipt of th
r explorato
r explorato
ministered 
ministered
will be adm
will be adm
ials)
als) on day
on d
main on trea
main on tre
, unaccepta
unaccept
bject refusa
bject refus
iew of Effi
iew of Effi
subjects w
subjects w
acco
cc rding 
ding 
ando
andom

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Response assessments will include computed tomography (CT) scan or magnetic resonance 
imaging (MRI) of the chest, upper abdomen, including whole liver and kidney and, if clinically 
indicated, pelvis. Pelvis scan should be performed only with MRI unless CT is local standard of 
care at the site. Bone scans will only be performed at baseline if clinically indicated. If the 
baseline bone scan is suggestive of metastasis, a CT or MRI should be performed and further 
follow-up of these lesions will follow the protocol schedule. Bone scans during the trial will only 
be performed if clinically indicated.  If suggestive of new lesions, a CT or MRI will be 
performed to confirm progression.
In the follow-up phase, anticancer treatment administered following the last dose of 
investigational product [(IP), also referred to as investigational medicinal product (IMP)] and 
survival will be followed every 8 weeks (± 5 days) until death, withdrawal of consent, or lost-to-
follow-up, whichever occurs first, or the End of Trial.
Overview of Safety Assessments
All subjects will be monitored for adverse events, starting from the time the subject signs the 
informed consent form (ICF) until 30 days after the last dose of either study drug. A thorough 
evaluation of medical conditions will be conducted during screening for eligibility. Documented
physical examination (PE), vital signs, laboratory assessments, (eg, serum chemistry, 
hematology), 12-lead electrocardiogram (ECG), urinalysis, and Eastern Cooperative Oncology 
Group (ECOG) performance status will be monitored regularly. Preventative measures will be 
taken to avoid pregnancy in study subjects or their partners, and females of child-bearing 
potential will have regular pregnancy testing performed. The full schedule of assessments is 
described in Table 2 and Section 6.
Overview of Statistical Methods
This is a double-blind, placebo-controlled, randomized, phase 2 trial designed to evaluate the 
efficacy and safety/tolerability of  CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo, in subjects with previously treated locally advanced or metastatic non-small cell lung 
cancer. The primary endpoint is PFS based on Investigator review.
Sample Size
The primary goal of this study is to provide estimates of the difference in efficacy and safety 
between CC-486 + pembrolizumab and placebo + pembrolizumab. Approximately 90 subjects 
will be randomized 1:1 to receive CC-486 plus pembrolizumab or placebo plus pembrolizumab. 
Primary analysis will be conducted when 70 PFS events occur. In this particular setting, a formal 
power calculation was not conducted.
Efficacy Analysis
Efficacy analyses will be performed using the intent-to-treat (ITT) population.
The median PFS in each stratum and treatment arm will be calculated based on Kaplan-Meier 
estimates along with corresponding two-sided 90% confidence interval (CI).  In addition, the 
Cox proportional hazards regression model with treatment and any stratification factors will be 
performed to obtain the point estimate of hazard ratio (HR) and two-sided 90% CI.  
The secondary efficacy endpoint of OS will be analyzed similarly to PFS.  Other secondary 
endpoints of overall response rate (ORR), and disease control rate (DCR) will be evaluated as 
&(/*(1(35235,(7$5<,1)250$7,21
and 
and
or 
or lolostst-toto
e subject si
e subject si
tudy
dy drug
drug
y
A
for eligibil
for eligibi
g, serum ch
 serum ch
Eastern
Easte
C
rly
rly. Preven
Preven
rs, and fem
rs, and fem
d. The full 
d. The full
randomized
andomize
86 pl
86 plus
us
l
pem
p
reated
reated lol ca
FS based on
based on
tudy
dy i
y s to p
s to p
mbrolizuma
mbrolizuma
1:1 to recei
1 to rece
will be con
will be con
ion was no
n was n
Analysis
nalysis
cy analyses
cy analyse
he m
he median P
edian 
estimates 
stimates 
ox pr
ox pr

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
well. A two-sided 90% CI of the difference in ORR and DCR between the two treatment arms 
will be provided. 
Safety Analysis
Safety analysis will be performed using the safety population. Safety and tolerability will be 
monitored through continuous reporting of adverse events (AEs) and serious adverse events 
(SAEs), laboratory abnormalities, and incidence of subjects experiencing adverse events 
resulting in dose reductions, dose interruptions, and/or premature discontinuation of study drugs. 
Treatment-emergent adverse events (TEAEs), TEAEs leading to death or discontinuation from 
treatment, events assessed as Grade 3 or Grade 4,  vital signs, weight, clinical laboratory 
information, and concomitant medications/procedures will be tabulated and summarized.
All AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA). 
All TEAEs will be summarized by system organ class and preferred term, frequency, severity 
grade based on the Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) 
and relationship to treatment. Serious TEAEs, TEAEs of interest, and TEAEs leading to 
discontinuation, dose reduction, or interruption,  or death will be summarized/ listed separately.
&(/*(1(35235,(7$5<,1)250$7,21
m 
d.
s (MedDR
s (MedDR
ency, severi
ncy, sever
AE) (Versio
AE) (Versi
AEs leading
Es leading
arized/ liste
zed/ li

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................17
1.1.
Disease Background ...............................................................................................17
1.2.
Treatment Options in Second-line Metastatic NSCLC ............................................17
1.3.
Overview of CC-486...............................................................................................19
1.3.1.
CC-486 Experience in Solid Tumors.......................................................................21
1.4.
Overview of Pembrolizumab ..................................................................................22
1.4.1.
Pembrolizumab Experience in Solid Tumors and Safety.........................................22
1.5.
Study Rationale ......................................................................................................23
2.
STUDY OBJECTIVES...........................................................................................25
2.1.
Primary Objective...................................................................................................25
2.2.
Secondary Objectives .............................................................................................25
2.3.
Exploratory Objectives ...........................................................................................25
3.
STUDY ENDPOINTS............................................................................................26
3.1.
Primary Endpoint....................................................................................................26
3.2.
Secondary Endpoints ..............................................................................................26
3.3.
Exploratory Endpoint(s)..........................................................................................26
4.
OVERALL STUDY DESIGN ................................................................................27
4.1.
Study Design ..........................................................................................................27
4.2.
Study Duration .......................................................................................................28
4.3.
End of Trial ............................................................................................................28
5.
TABLE OF EVENTS.............................................................................................29
6.
PROCEDURES......................................................................................................34
6.1.
Screening Period.....................................................................................................34
6.2.
Treatment Period ....................................................................................................35
6.2.1.
End of Treatment....................................................................................................36
6.3.
Follow-up Period....................................................................................................37
6.3.1.
Efficacy Follow-up.................................................................................................37
6.3.2.
Survival Follow-up.................................................................................................37
6.4.
Response Assessments............................................................................................37
&(/*(1(35235,(7$5<,1)250$7,21
7
....... 19
19
...........
.......... 21
2
.............
............
..............
............
.............
............
.............
.............
........
..
......
.....
.............
.........
..............
...
................
........
.............
.............
.............
.............
..............
........
IGN
IGN ......
..
..............
.............
..............
.........
.............
.........
OF EVENT
OF EVEN
CEDURES
CEDURES
Screening P
Screening P
Treatme
Treatm
.
End
En
.3.
.3.
.3.1.
.3.1.

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
6.4.1.
Assessment of Response According to RECIST Version 1.1...................................38
6.4.2.
Assessment of Response According to irRECIST ...................................................38
6.4.3.
Assessment of Disease and Treatment after Initial Radiologic Progression .............38
6.5.
Pharmacokinetics....................................................................................................39
6.6.
Biomarkers .............................................................................................................40
6.7.
12-lead Electrocardiogram......................................................................................40
7.
STUDY POPULATION.........................................................................................41
7.1.
Number of Subjects and Sites .................................................................................41
7.2.
Inclusion Criteria....................................................................................................41
7.3.
Exclusion Criteria...................................................................................................42
8.
DESCRIPTION OF STUDY TREATMENTS........................................................45
8.1.
Description of Investigational Products...................................................................45
8.1.1.
CC-486 (Oral Azacitidine)/Placebo.........................................................................45
8.1.2.
Pembrolizumab.......................................................................................................45
8.2.
Treatment Administration and Schedule .................................................................45
8.2.1.
Dose Adjustment Guidelines...................................................................................46
8.2.1.1.
CC-486 (oral azacitidine)/Placebo ..........................................................................46
8.2.1.2.
Pembrolizumab.......................................................................................................48
8.2.2.
Overdose ................................................................................................................50
8.3.
Method of Treatment Assignment...........................................................................51
8.4.
Packaging and Labeling..........................................................................................51
8.5.
Investigational Product Accountability and Disposal ..............................................51
8.6.
Investigational Product Compliance........................................................................51
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................52
9.1.
Permitted Concomitant Medications and Procedures...............................................52
9.1.1.
CC-486 (oral azacitidine)........................................................................................52
9.1.2.
Pembrolizumab Supportive Care.............................................................................52
9.1.2.1.
Management of pneumonitis...................................................................................53
9.1.2.2.
Management of Diarrhea/Colitis.............................................................................53
9.1.2.3.
Management of type 1 diabetes mellitus (if new onset, including diabetic 
ketoacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic acidosis (DKA) ................................................................53
9.1.2.4.
Management of hypophysitis ..................................................................................53
&(/*(1(35235,(7$5<,1)250$7,21
0
.......41
4
..........
.... 41
4
..............
...........
..............
............
.............
.............
..............
............
.............
......
.........
..... ....
..............
...........
..........
.............
.............
............
..............
..........
.............
..........
ignment
gnmen ..
ng...........
.........
oduct Acco
oduct Acc
al Product C
al Product C
MITANT M
ITANT
tted Conco
tted Conco
C-486 (ora
486 (ora
Pembrol
Pembro
1.1.
Man
Ma
.1.2.2.
.1.2.2.
9.1.2.3.
.1.2.3

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
9.1.2.5.
Management of hyperthyroidism or hypothyroidism...............................................54
9.1.2.6.
Management of hepatic abnormalities.....................................................................54
9.1.2.7.
Management of renal failure or nephritis.................................................................54
9.1.2.8.
Management of infusion reactions ..........................................................................54
9.2.
Prohibited Concomitant Medications and Procedures..............................................56
9.3.
Required Concomitant Medications and Procedures................................................57
10.
STATISTICAL ANALYSES..................................................................................58
10.1.
Overview................................................................................................................58
10.2.
Study Population Definitions ..................................................................................58
10.2.1.
Intent-To-Treat Population .....................................................................................58
10.2.2.
Safety Population....................................................................................................58
10.2.3.
PK Population ........................................................................................................58
10.2.4.
Biomarker Population.............................................................................................58
10.3.
Sample Size and Power Considerations...................................................................58
10.4.
Background and Demographic Characteristics........................................................59
10.5.
Subject Disposition.................................................................................................59
10.6.
Efficacy Analysis....................................................................................................59
10.6.1.
Primary Efficacy Endpoint......................................................................................59
10.6.2.
Secondary Endpoints ..............................................................................................60
10.6.2.1.
Overall Survival .....................................................................................................60
10.6.2.2.
Overall Response Rate (ORR) ................................................................................60
10.6.2.3.
Disease Control Rate (DCR)...................................................................................60
10.6.2.4.
irPFS, irORR and irDCR per irRECIST..................................................................60
10.6.3.
Subgroup Analysis..................................................................................................60
10.7.
Safety Analysis.......................................................................................................60
10.8.
Pharmacokinetic Analysis.......................................................................................61
10.8.1.
Plasma Concentrations............................................................................................61
10.8.2.
Pharmacokinetic Parameters...................................................................................62
10.8.3.
PK Analyses...........................................................................................................63
10.9.
Interim Analysis .....................................................................................................63
10.10.
Other Topics...........................................................................................................63
10.10.1.
Data Monitoring Committee ...................................................................................63
10.10.2.
Steering Committee ................................................................................................63
7
.......58
5
..........
.... 58
5
..............
...........
..............
............
.............
.............
..............
............
.............
.............
.............
.....
..............
...........
.............
.............
.............
............
..............
..........
.............
..........
.............
....
e (ORR)
e (ORR) .
Rate (DCR)
Rate (DCR
and i
nd irDCR
rDCR
i
Analysis
Analysi
y y Analysis
Analysis
harmacokin
armacoki
Pl
P asma 
asma 
2.2.
Phar
Ph
0.8.3.
0.8.3.
10.9.
0.9.

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
11.
ADVERSE EVENTS..............................................................................................65
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................65
11.2.
Evaluation of Adverse Events.................................................................................66
11.2.1.
Seriousness.............................................................................................................66
11.2.2.
Severity / Intensity..................................................................................................67
11.2.3.
Causality ................................................................................................................67
11.2.4.
Duration .................................................................................................................68
11.2.5.
Action Taken..........................................................................................................68
11.2.6.
Outcome.................................................................................................................68
11.3.
Abnormal Laboratory Values..................................................................................68
11.4.
Pregnancy...............................................................................................................68
11.4.1.
Females of Childbearing Potential ..........................................................................69
11.4.2.
Male Subjects.........................................................................................................69
11.5.
Reporting of Serious Adverse Events......................................................................69
11.5.1.
Safety Queries ........................................................................................................70
11.6.
Expedited Reporting of Adverse Events..................................................................70
11.7.
Pembrolizumab Events of Clinical Interest .............................................................71
12.
DISCONTINUATIONS .........................................................................................73
12.1.
Treatment Discontinuations ....................................................................................73
12.2.
Study Discontinuation ............................................................................................73
13.
EMERGENCY PROCEDURES.............................................................................74
13.1.
Emergency Contact.................................................................................................74
13.2.
Emergency Identification of Investigational Products .............................................74
14.
REGULATORY CONSIDERATIONS...................................................................75
14.1.
Good Clinical Practice............................................................................................75
14.2.
Investigator Responsibilities ...................................................................................75
14.3.
Subject Information and Informed Consent.............................................................76
14.4.
Confidentiality........................................................................................................76
14.5.
Protocol Amendments.............................................................................................76
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................76
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................77
14.8.
Termination of the Study ........................................................................................77
&(/*(1(35235,(7$5<,1)250$7,21
7
.......68
6
..........
.... 68
6
..............
...........
..............
............
.............
.............
..............
............
.............
......
..........
..... ...
..............
...........
.............
.............
rest
rest .......
...
..............
..........
.............
..........
.............
....
EDURES
DURE
ctct...........
......
entificati
tifica on
TORY CO
TORY C
Clinical Pr
Clinical P
nvest
estigator 
igator
Subject 
Subject 
Con
Co
4.5.
4.5.
14.6.
4.6.

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
14
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
15.
DATA HANDLING AND RECORDKEEPING.....................................................78
15.1.
Data/Documents .....................................................................................................78
15.2.
Data Management...................................................................................................78
15.3.
Record Retention....................................................................................................78
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................80
16.1.
Study Monitoring and Source Data Verification......................................................80
16.2.
Audits and Inspections............................................................................................80
17.
PUBLICATIONS ...................................................................................................81
18.
REFERENCES.......................................................................................................82
19.
APPENDICES........................................................................................................85
19.1.
Appendix A: RECIST 1.1.......................................................................................85
19.1.1.
Definitions..............................................................................................................85
19.1.1.1.
Measurable Disease ................................................................................................85
19.1.2.
Tumor Response Evaluation ...................................................................................85
19.1.2.1.
Target Lesions........................................................................................................85
19.1.2.2.
Non-target Lesions .................................................................................................86
19.1.2.3.
Response Criteria....................................................................................................86
19.1.2.4.
Symptomatic Deterioration.....................................................................................88
19.2.
Appendix B: irRECIST...........................................................................................89
19.3.
Appendix C: Table of Abbreviations.......................................................................99
&(/*(1(35235,(7$5<,1)250$7,21
0
.......80
8
..........
.... 81
8
..............
...........
..............
............
.............
.............
..............
............
..........
......... .....
.............
.....
..............
...........
.............
.............
.............
............
..............
..........
.............
..........
breviat
breviatioi ns

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
15
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
LIST OF TABLES
Table 1:
Main Data in Pretreated NSCLC Subjects...............................................................18
Table 2:
Table of Events.......................................................................................................29
Table 3:
Imaging and Treatment after Site-Assessed 1st Radiologic Evidence of PD............39
Table 4:
Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase..........................................................................................40
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity ...........................47
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events.....................................................................................................................49
Table 7:
Infusion Reactions..................................................................................................55
Table 8:
Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio ..................59
Table 9:
Time Point Response: Subjects With Target (± Non-target) Disease .......................87
Table 10:
Time Point Response: Subjects With Non-target Disease Only ...............................88
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) 
RECIST..................................................................................................................89
Table 12:
Abbreviations and Specialist Terms........................................................................99
&(/*(1(35235,(7$5<,1)250$7,21
0
......47
.............
.......
4
..............
...
Ratio
Rati .......
Disease
sease ...
 Only
Only .....
mune-
un relat
lat
..............
............
.............
..........

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
16
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
LIST OF FIGURES
Figure 1:
Overall Study Design..............................................................................................28
&(/*(1(35235,(7$5<,1)250$7,21

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
1.
INTRODUCTION
1.1.
Disease Background
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in both men 
and women. Globally, approximately 1,825,000 new cases of lung cancer were diagnosed in
2012, and 1,590,000 deaths occurred due to this disease (Globocan, 2012). The World Health
Organization (WHO) divides lung cancer into 2 major classes based on its biology, therapy, and 
prognosis: NSCLC and small cell lung cancer. NSCLC accounts for more than 85% of all lung 
cancer cases and includes 2 major types: (1) non-squamous carcinoma (including 
adenocarcinoma, large-cell carcinoma, other cell types); and (2) squamous cell (epidermoid) 
carcinoma. Adenocarcinoma (40% of lung cancers) is the most common type of lung cancer seen 
in the United States (US) and is also the most frequently occurring cell type in nonsmokers 
(Speicher, 2000).
Cigarette smoking remains the most important risk factor for lung cancer, although 
approximately 15% of all lung cancers are diagnosed in patients who never smoked.
One reason for the high mortality rate of lung cancer is the advanced stage at diagnosis; only 25-
30% of new NSCLC cases are diagnosed with localized disease that is potentially curable with 
surgery (Fossella, 2000; Lang-Lazdunski, 2013). The majority of patients are diagnosed with 
locally advanced or metastatic disease and are not candidates for surgery.
1.2.
Treatment Options in Second-line Metastatic NSCLC
In patients with metastatic NSCLC who have experienced disease progression either during or 
after first-line therapy and have an Eastern Cooperative Oncology Group (ECOG) performance 
score of 0-2, single agent docetaxel, gemcitabine, or erlotinib is recommended if not previously 
given. Pemetrexed is another option for the non-squamous subtype of NSCLC (NCCN, 2014, 
ESMO, 2014).  
Docetaxel was shown to be superior to best supportive care (BSC), vinorelbine and ifosfamide; 
nevertheless, using either the weekly or three-weekly schedule in multiple randomized studies 
the observed response rate with docetaxel ranged from 3% to 12%, progression-free survival 
(PFS) from 1.9 to 3.4 months, and overall survival (OS) from 5.4 to 9.2 months (Shepherd, 2000; 
Fossella, 2000; Bria, 2006).
Recently, nintedanib, a triple angiokinase inhibitor, was approved in the European Union (EU) in 
combination with docetaxel as second-line therapy for NSCLC. The results showed that 
compared to docetaxel alone, nintedanib plus docetaxel significantly extended the median OS
from 10.3 to 12.6 months for patients with advanced adenocarcinoma, after first-line 
chemotherapy (P=0.0359; hazard ratio [HR]: 0.83) (Reck, 2014). In addition, ramucirumab was 
approved in the US in combination with docetaxel as second-line therapy. The phase 3 REVEL 
trial compared ramucirumab, a vascular endothelial growth factor (VEGFR)-2 antagonist, plus 
docetaxel with placebo plus docetaxel in NSCLC patients who experienced disease progression 
after treatment with platinum-based chemotherapy for locally advanced or metastatic disease.
Median OS was better in the ramucirumab group than in the placebo group (10.5 vs 9.1 months; 
&(/*(1(35235,(7$5<,1)250$7,21
nd
lung 
lung 
ermo
ermoid) 
id) 
ung cancer 
ng cancer
nonsm
nonsmoker
ok
er, although
althou
never smo
never sm
nced stage a
ed stage 
se that is po
se that is 
rity
ty
i
of
of
y
pat
pat
f
ie
dates for su
dates for 
ne Metas
Metas
experience
experience
Cooperativ
Cooperati
mcicitabine
tabine
i
, o
fofor the non
r the 
perior to be
perior to b
he weekly o
weekly
ate w
ate ith doc
h d
months, an
months, 
a, 2006
, 2006).).
edanib
danib, a tr
a 
n wi
n with
th
i
doce
doce
h
d to doceta
o docet
10.3 to 12.
10.3 to 12
emotherapy
motherapy
approved i
pproved i
ririalal co
co
l

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
HR, 0.857; P = .0235), as was median PFS (4.5 vs 3.0 months; HR, 0.762; P < .0001) (Perol,
2014).
Gemcitabine showed modest activity in a phase II study with a 6.2% partial response and 17 
weeks median duration of survival in advanced NSCLC subjects who progressed on first-line 
cisplatin-containing therapy (Sculier, 2000).  Another phase II study found a partial response in
19% of subjects treated with gemcitabine as a second-line agent, and a median duration of 
response of 29 weeks (Crino, 1999).  In a third trial evaluating gemcitabine plus BSC versus 
BSC alone, tumor response was seen in 19% of gemcitabine-treated subjects while response was 
not measured in subjects treated with BSC alone (Anderson, 2000).  There was no difference in 
OS (5.7 versus 5.9 months, respectively).   The difference in the results between the trials may be 
due to the percentage of stage III versus stage IV subjects included in the trials.  In the study by 
Sculier et al. 96% of subjects had stage IV disease compared to 59% and 40% in Crino et al. and 
Anderson et al., respectively.
Erlotinib has been proven to be superior to BSC with significantly improved survival (6.7 vs. 4.7 
months), PFS (2.2 vs. 1.8 months), and delayed time to symptom deterioration (Shepherd, 2005).
Gefitinib is approved in the EU for the treatment of advanced and metastatic NSCLC with 
activating mutations of epidermal growth factor receptor (EGFR) only. Although a higher 
response rate was in favor of gefitinib compared to placebo (8% vs. 1%), median time to 
progression (TTP) (3.0 vs. 2.6 months) and survival (5.6 vs. 5.1 months) were similar in the 2
groups (Thatcher, 2005). A non-inferiority trial compared gefitinib to docetaxel in NSCLC 
patients after 1 or 2 lines of chemotherapy (Kim, 2008). A similar median survival (7.6 vs. 8 
months) and TTP (2.2 vs. 2.7 months) were observed, but less toxicity and better quality of life 
favored the gefitinib arm.
Pemetrexed showed clinically equivalent efficacy outcomes but better tolerability when 
compared to docetaxel in patients with the non-squamous subtype of NSCLC (Hanna, 2004; 
Peterson, 2007). 
An overview of the published data with the above described agents are summarized in Table 1.
Table 1:
Main Data in Pretreated NSCLC Subjects
Compound
Line of 
treatment
Histology
N
RR (%)
Median 
TTP/PFS 
(months)
OS 
(months)
Docetaxel
2nd
All
2557
2.7-12.6
1.9-3.4
5.4-9.2
Gemcitabine
2nd
All
65
6.21
--
4.22
Erlotinib
2nd 3rd
All
806
6.2-9
1.7-2.2
6.7-9.2
Gefitinib
2nd 3rd
All
1862
8.0-9.1
2.2-3.0
5.6-7.6
Pemetrexed
2nd
All3
871
4.3-9.1
2.6-2.9
6.7-8.3
1 This value represents partial response.
2 This value represents median duration of survival.
3 A retrospective analysis found that pemetrexed only showed significantly higher survival when compared to docetaxel in the 
non-squamous subgroup.  Docetaxel had statistically better survival in the squamous cell subgroup
&(/*(1(35235,(7$5<,1)250$7,21
as 
as 
e inin
may 
may be
be
e study
study by
by
y
ino et al. a
ino et al. a
d survival (6
d survival 
ati
ation (
on (Shep
etastatic NS
tastatic N
only
n . Alt
Altho
h
% vs. 1%), m
vs. 1
5.1
5.1 mo
m nth
d gefit
gefitinib t
inib t
). A simila
). A simila
ed, but less 
ed, but les
ficacy
ficacy ou
ou
y
tctc
u
e non
e non-squa
squa
a with the ab
with the a
Pretreated
retreate
f f 
ment
ment
H
35
(
2nd
nd
1(
2nd
(1
*
2n
*(
/*
inib
inib
/*
/*
/*
/*
Pemetrexed
emetrexed
&(
&
This va
This va
i

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Personalized treatment based on molecular characteristics of the tumor has also become the 
standard of care.  In addition to the above guidelines, patients whose tumors are positive for the 
EGFR and/or anaplastic lymphoma kinase (ALK) mutation(s) should receive targeted therapy.  
The EGFR mutation which results in the activation of the EGFR tyrosine kinase domain has 
been reported in about 20-25% of non-squamous NSCLC cases and less than 5% in tumors with 
squamous histology.  Erlotinib and afatinib are EGFR tyrosine kinase inhibitors (TKIs) indicated 
for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 
deletions or exon 21 (L858R) substitution mutations, the most commonly found mutations in 
NSCLC (Tarceva® Package Insert; Gilotrif® Package Insert; NCCN, 2014).  Patients who 
progress after first-line therapy are still recommended to be continued on erlotinib or afatinib as 
part of second-line therapy (NCCN, 2014).  Anaplastic lymphoma kinase translocation, another 
key driver mutation, occurs in roughly 5% of NSCLC cases (Shaw, 2013), and it is mostly 
associated with the adenocarcinoma subtype (Bang, 2011; Xalkori Package Insert).  Tumors with 
this mutation are amenable to treatment with crizotinib, an ALK, MET, and ROS1 tyrosine 
kinase inhibitor, and thus, crizotinib is used in first-line therapy for metastatic ALK-positive 
NSCLC patients.  For patients who progress after first-line therapy, crizotinib or the recently 
approved ALK inhibitor, ceritinib, is recommended as part of second-line therapy (NCCN, 
2014).  This trial will focus on second-line therapy for subjects who do not possess these 2 driver 
mutations.  Thus, EGFR-positive and ALK-positive subjects will be excluded from this trial.  
The reported response rate to second-line therapy has generally been less than 10% (NCCN, 
2014), and many patients who respond to second-line therapy eventually develop resistance.  The 
limited effective second-line therapy options available call for the investigation of novel 
approaches to drug therapy in advanced NSCLC.
1.3.
Overview of CC-486
CC-486 is an orally bioavailable formulation of azacitidine (AZA).  Azacitidine, an analog of the 
pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and 
deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
Vidaza® (azacitidine injection) is approved by the US Food and Drug Administration (FDA) for 
five subtypes of the French American British (FAB) classification system of myelodysplastic 
syndrome (MDS) and chronic myelomonocytic leukemia (CMMoL). Vidaza is also approved by 
the European Commission for the treatment of adult MDS, acute myeloid leukemia (AML) and 
CMMoL patients who are not eligible for hematopoietic stem cell transplantation.  Vidaza can be 
administered by intravenous (IV) or subcutaneous (SC) routes as designated by country 
approval.
After its incorporation into a cell’s DNA during the S-phase of the cell cycle, AZA forms 
covalent adducts with DNA methyltransferase 1 (DNMT1) and depletes this enzyme required for 
the maintenance of DNA methylation patterns, thereby altering the epigenetic status of the cell.   
Epigenetic changes are covalent modifications of chromatin (DNA and histone proteins) that 
mediate the stable transmission of a gene’s transcriptional status through cell division.  One of 
the first recognized epigenetic alterations in cancer was DNA methylation.  The addition of a 
methyl group to cytosine in the dinucleotide CpG is catalyzed by DNA methyltransferases 
(DNMTs) and is associated with transcriptional suppresion of genes (Miranda, 2007).  Genomic 
methylation patterns are precisely regulated during normal embryonic development and 
&(/*(1(35235,(7$5<,1)250$7,21
nib as 
nib as 
another 
another 
mostly
ostly
).  Tumors 
 Tumors
OS1 ty
S1 tyrosin
ros
y
tic ALK
tic ALK-po
p
tinib or the
inib or
line therap
line therap
o do not po
o do not p
ll be exclud
ll be exclud
ally been le
ally been le
erapy event
rapy eve
call for th
call for th
ioion of a
n of aza
fects on ce
fects on ce
hesis and m
sis and m
) is approve
s approve
American B
American
ronic myelo
ronic my
sion for the
sion for the
who are not 
who are not 
intntravenou
ravenou
incorporati
orporati
nt adducts 
t adducts 
maintenan
maintenan
Epi
Epigeneti
genetic
mediate 
mediat
e fir
fi

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
differentiation and have been found to be altered in specific ways in cancer.  Specifically, cancer 
cell genomes are typified by reduced methylation globally with focal areas of aberrant 
hypermethylation in the CpG islands of genes encoding known tumor suppressors such as PTEN 
and BRCA1 as well as genes encoding proteins required for apoptosis, including caspase 8, 
DAPK and Apaf-1.  DNA methylation-based gene silencing can thus contribute to the 
establishment and maintenance of the transformed state and limit the effectiveness of anticancer 
therapies.
CC-486 entered clinical testing in 2006 in subjects with MDS, CMMoL, and AML.  The AZA 
PH US 2007 CL 005 study has shown that CC-486 is bioavailable and a maximum tolerated dose 
(MTD) of 480 mg daily for 7 days of a 28-day cycle was defined based on dose-limiting diarrhea 
at the 600 mg dose (Garcia-Manero, 2011).  As expected, reversible and manageable 
myelosuppression was observed.  Pharmacodynamic activity (DNA hypomethylation) and 
clinical responses were observed with CC-486, although the cross-over design (with SC Vidaza 
administered during Cycle 1) confounded the interpretation of these responses in Part 1 of the 
study.
The second part of the AZA PH US 2007 CL 005 study explored both daily and twice daily 
extended dosing schedules of 14 and 21 days out of 28 days in a non-crossover design.  CC-486 
administered at 300 mg once daily (QD) for 14 or 21 days of a 28-day cycle produces cumulative 
exposures (area under the concentration-time curve [AUC] per cycle) that are approximately 
40% and 60% of the exposure achieved with the labeled dose and schedule of Vidaza, 
respectively.  Daily doses of 300 mg have proven to be tolerated on both the 14 and 21 out of 28-
day schedules with myelosuppression, gastrointestinal (GI) symptoms, and fatigue being the 
most common toxicities (Garcia-Manero, 2011).
In the AZA PH US 2007 CL 005 study, DNA methylation levels in blood were measured as a 
pharmacodynamic (PD) endpoint, to determine DNA hypomethylating activity of CC-486.  In 
summary, it was confirmed that CC-486 is biologically active, reducing DNA methylation when 
administered at low doses on extended schedules.
CC-486 is also under clinical investigation, either as monotherapy or in combination with other 
investigational products, for the treatment of lymphoma, multiple myeloma, and relapsed or 
refractory solid tumors (eg, urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra; 
pancreatic carcinoma; breast cancer; ovarian cancer; nasopharyngeal carcinoma; cervical 
carcinoma; anal carcinoma; and merkel cell carcinoma).  
 
  There are 2 ongoing studies evaluating 
PK of CC-486 (AZA-ST-001 and CC-223-NSCL-001). Part 1 of the AZA-ST-001 study 
assessed the impact (if any) of carboplatin or ABI-007 on the PK of CC-486 and the impact (if 
any) of CC-486 on the PK of carboplatin or ABI-007.  Preliminary results showed that in 
subjects from Arms A and B, following administration of CC-486 alone or in combination with 
carboplatin or ABI-007, azacitidine was rapidly absorbed and reached Tmax within approximately 
1.0 hour post-dose (median); azacitidine PK parameters (AUC, Cmax, t1/2, CL/F, and Vz/F) were 
comparable following administration of CC-486 alone or in combination.  Similarly, carboplatin 
and ABI-007 PK parameters were similar following administration of carboplatin or ABI-007 
alone or in combination with CC-486.  In subjects from the 3 arms (Arms A, B, and C, i.e., CC-
486 monotherapy), global genomic hypomethylation was observed in PBMCs, with maximum 
(AZA
(AZA-ST
ST 0
impact (if 
impact (if
C-486 on t
486 on t
ts fro
ts fr m Ar
Ar
bopl
oplatatin or 
in or 
1.0 hour po
.0 hour po
com
ompara
par
m
d A
d A
1(35235,(7$5<,1)250$7,21
dose
dos
diarrhea
arrhea
on) and 
n) and 
wi
with
th
i
SC Vi
SC Vi
h
s in Part 1 
s in Part 1 
daily and t
daily and 
n-crosso
rossove
8-day
da cycle
cl
y
er cy
er cycle) tha
cle) t
se and sch
e and sc
tolerated o
tolerated o
al (GI) sym
al (GI) sy
methylat
ethylatioio
mine DNA 
ine DNA
is bi
s biol
ologic
og
d schedule
d sched
est
estigat
igatioion
he treatmen
he treatme
, urothelial 
urothelia
reast cance
reast canc
no
noma
ma; and
; an
(1(

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
effect on Day 15.  A PK/PD (AUC/hypomethylation change on Day 15) correlation was noted (r 
> 0.5; p < 0.01).
1.3.1.
CC-486 Experience in Solid Tumors
A Phase 1 study of CC-486 in combination with carboplatin or nab-paclitaxel, or as a single 
agent in subjects with relapsed or refractory solid tumors (AZA-ST-001) was initiated on 30 Nov 
2011.  In Part 1 of this two-part study, CC-486 at escalating doses of 200 or 300 mg was 
administered on Days 1 to 14 of a 21-day cycle in three separate arms of the study (Arm A, Arm 
B, Arm C). 
In Arm A of AZA-ST-001, subjects received carboplatin (AUC = 4) on Day 8 of each cycle and 
in Arm B, subjects received nab-paclitaxel 100 mg/m2 beginning on Day 8.  For Arm A, both 
200 mg and 300 mg CC-486 were well tolerated with carboplatin AUC = 4.  For Arm B, 
initially, nab-paclitaxel was administered weekly starting on Cycle 1 Day 8 but dose-limiting 
neutropenia was encountered on this schedule at the first dose level of CC-486.  The protocol 
was amended to administer nab-paclitaxel on Days 8 and 15 of each cycle (ie, 2 out of 3 weeks) 
and this was well tolerated in combination with CC-486 at 200 mg.  When the CC-486 dose was 
escalated to 300 mg, dose-limiting neutropenia was again encountered, making the 200 mg the 
MTD of CC-486 in combination with nab-paclitaxel 100 mg/m2 on a 2- out of 3-week schedule.  
Arm C of study AZA-ST-001 assessed the safety of continuous administration of CC-486 on a 
21- out of 21-day schedule.  This schedule proved not to be tolerable, with profound 
granulocytopenia manifesting in 2 out of 6 subjects at the 300 mg dose level during Cycle 2.  
Single agent CC-486 was better tolerated in subjects when used at the dose of 300 mg daily for 
2- out of 3-week cycle with a manageable safety profile, and the recommended Phase 2 dose for 
Arm C was determined to be 300 mg on Days 1 to 14 of each 21-day cycle.
 
 
 
 
The most promising hints of activity in AZA-ST-001 were observed in Arm B.  Of 8 evaluable 
subjects with relapsed pancreatic carcinoma, 1 had a partial response (PR) and 3 others had 
stable disease (SD) > 16 weeks for a disease control rate (DCR) of 50%.  CC-486 has also shown 
promising efficacy in subjects with relapsed or refractory NSCLC (N = 20).  Although the 
efficacy data are not yet fully mature, objective responses were observed, including 2 PRs in 
NSCLC subjects. An additional 8 subjects with NSCLC had stable disease for periods ranging 
from 4 to 9 months. Furthermore, dramatic objective responses were observed in subjects with 
relapsed cervical and endometrial cancer.  These observations, although promising, do not 
provide conclusive evidence of an epigenetic modifying effect by CC-486.
Please refer to the Azacitidine IB for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event (AE) profile of 
the azacitidine/CC-486.
&(/*(1(3523
ctivit
ctivity y in A
in
reat
eatic carci
c carc
weeks for 
weeks fo
subjects w
subjects 
ot y
ot yet f
et fully
ully
f
s. An addit
s. An addit
months.
onths. Fur
Fur
ervical and
vical and
e concl
conclusiv
usiv
l
ase refer to
se refer to
pharmaco
pharmacol
he azac
e aza
5,(7$5<,1)250$7,21
m
ycle and 
le and 
A, both
A, both
Arm B, 
Arm B, 
dose
dose-limit
lim
86.  
6.  The pro
The p
e (ie, 2 out 
e (ie, 2 out 
hen the CC
hen the C
red, making
d, making
on a 2
 a - out
ou
s administ
s admin
e tolerable, 
tolerable
he 300 mg d
300 mg
when used 
when used
rofile, and 
rofile, and 
 to 14 of ea
to 14 of 
35,(
35
235

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
1.4.
Overview of Pembrolizumab
The programmed cell death protein-1 (PD-1) is an immune-checkpoint receptor expressed by T 
cells upon activation.  The normal function of PD-1 upon binding by its ligands, programmed 
death-ligand 1 (PD-L1) and PD-L2, is to moderate ongoing immune responses and prevent 
autoimmunity (Harvey, 2014).  Some tumor cells up-regulate the PD-1 ligands to evade active T-
cell immune surveillance. Pembrolizumab is a highly selective humanized monoclonal antibody 
(mAb) that binds to the PD-1 receptor and directly blocks the interaction between PD-1 and its 
ligands, thereby enhancing tumor regression and ultimately immune rejection (pembrolizumab
IB).  Pembrolizumab is being investigated in various oncology indications including melanoma, 
NSCLC, renal cell carcinoma (RCC), breast cancer, multiple myeloma (MM), microsatellite 
unstable tumors, and head and neck cancer. Pembrolizumab [Keytruda (US)],  is approved for 
treatment of melanoma in several countries; in the US it is indicated for the treatment of 
advanced, unresectable or metastatic malignant melanoma in patients with disease progression 
after prior treatment with ipilimumab and, for BRAF V600 mutation-positive patients, a BRAF 
inhibitor, while in the EU it is approved for the treatment of advanced (unresectable or 
metastatic) melanoma in adults. Pembrolizumab has also been granted approval in the US for the 
treatment of patients with metastatic NSCLC whose tumors express PD-L1 as determined by an 
FDA-approved test, and who have disease progression on or after platinum-containing 
chemotherapy.
1.4.1.
Pembrolizumab Experience in Solid Tumors and Safety
An open-label phase 1 trial (Keynote 001) is being conducted to evaluate the safety and clinical 
activity of single agent pembrolizumab. The dose escalation portion of this trial evaluated three 
dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks, in subjects with 
advanced solid tumors. All 3 dose levels were well tolerated and no dose-limiting toxicities
(DLTs) were observed. Based on PK data showing a half-life of  21 days, the dosing frequency 
in the expansion cohort has been changed to every 3 weeks. 
The choice of the 200 mg every 3 weeks as an appropriate dose for the switch to fixed dosing is 
based on simulations performed using the population PK model of pembrolizumab showing that 
the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent 
with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient 
exposures in the exposure range established in melanoma as associated with maximal efficacy 
response and 3) will maintain individual patients exposure in the exposure range established in 
melanoma that are well tolerated and safe. 
The ongoing expansion cohort in Keynote 001 is enrolling subjects with NSCLC.
Keynote 001, Part C enrolled 495 subjects with NSCLC (adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma) to receive monotherapy pembrolizumab. The ORR was 
19.4% (18.0% in the 394 previously treated subjects and 24.8% in the 101 previously untreated 
subjects). The median PFS was 3.7 months, and the median OS was 12.0 months (Garon, 2015).
Pembrolizumab has been generally well-tolerated. The most common treatment related adverse 
events were fatigue (19.4%), pruritus (10.7%), and decreased appetite (10.5%). Adverse events 
of grade 3 or higher were reported in 47 of 495 patients (9.5%). The only treatment-related 
adverse events of an inflammatory or immune-mediated nature that occurred in more than 2% of 
&(/*
no
no
/*(1(35235,(7$5<,1)250$7,21
oma,
ma,
litite
roved for 
oved for 
ent of 
ent of 
ase progres
ase progres
e pati
e patients, a
ts, a
resectable o
resectable o
approval in
approval 
PD-
D-L1 as d
L1 as 
r platinum
platinum
rs s and Saf
and S
onducted to
onducted
escalat
escalatioion
administere
dminister
re well tol
re well tol
a showing a
a showing a
ged to ever
ged to ever
weeks
week as a
as
d using the 
using the
ery 3 week
ery 3 wee
the 2 mg/k
the 2 m
sure range e
ure range e
l maintain 
l maintain 
re well tole
re well tol
g ex
g expansio
pansio
x
n
e 001, Part C
 001, Part
ma, and 
ma, and
.4% (18.0%
.4% (18.0%
subjects)
ubjects)
mbr
mbr

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
patients were infusion-related reactions (in 15 patients [3.0%]), hypothyroidism (in 34 patients 
[6.9%]), and pneumonitis (in 18 patients [3.6%]). One infusion reaction led to treatment 
discontinuation. All the patients with hypothyroidism were successfully treated with medical 
therapy. Pneumonitis of grade 3 or greater was observed in 9 patients (1.8%), including 1 (0.2%) 
who died. At the time of this analysis, 2 cases of pneumonitis (both grade 1 or 2) were ongoing 
(Garon, 2015).
Please refer to the pembrolizumab IB for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event (AE) profile.
1.5.
Study Rationale
Both CC-486 and pembrolizumab have shown promising activity and acceptable tolerability in 
patients with relapsed or refractory NSCLC as detailed in Sections 1.3.1 and 1.4.1.
The reported response rate to second-line therapy in NSCLC has generally been less than 10% 
(NCCN, 2014), and many patients who do respond eventually develop resistance.  The limited 
availability of effective second-line therapy options call for the investigation of novel approaches 
to drug therapy in advanced NSCLC.  One potential strategy is the use of epigenetic agents, such 
as CC-486, to prime the tumor to become more responsive to immunotherapy. This approach is 
proposed by combining CC-486 with pembrolizumab in this trial.
Studies have shown that epigenetic events such as hypermethylation of the promoter sites on 
certain genes may play a role in tumor progression in lung cancer (Topaloglu, 2004).  
Importantly, unlike gene mutations, DNA methylation is reversible and can be inhibited by a 
DNMTi (Zeng, 2013).  There are currently 4 drugs targeting epigenetic changes that have been 
approved by the FDA for use in hematologic malignancies, i.e., 2 DNMT inhibitors for 
myelodysplastic syndrome (azacitidine and decitabine) and 2 histone deacetylase (HDAC) 
inhibitors for cutaneous T-cell lymphoma (vorinostat and romidepsin). A recent study using the 
combination epigenetic therapy of azacitidine and entinostat, an HDAC inhibitor, in subjects 
with recurrent metastatic NSCLC who had extensive prior systemic therapy yielded some 
interesting results (Juergens, 2011).  Though only two of the 65 subjects had robust and durable
RECIST criteria responses to this therapy, a group of these subjects were observed during 
follow-up to have responded to various subsequent therapeutic regimens (Juergens, 2011). Five 
of these subjects received 1 of 2 investigational immunotherapy drugs, anti-PD1 or anti-PD-L1
antibody.  Preliminary data revealed that 3 subjects experienced durable partial responses for 
over a year while the other two subjects had stable disease on therapy for more than 6 months 
(Brahmer, 2013).  
Previous PD-1 immune-checkpoint targeting monotherapy studies in subjects with advanced 
NSCLC who received previous systemic therapy reported only a 16 to 17% response rate 
(Brahmer, 2012; Topalian, 2012, Brahmer, 2013 abstract, Garon 2014). 
The results of the above study led to the hypothesis that azacitidine may prime the tumor to 
become more responsive to immunotherapy.  There are several possible mechanisms as to how 
this may occur (Brahmer 2013): 
!
Azacitidine induces the type I IFN pathway and subsequently upregulates suppressed 
antigen-presenting molecules, enhancing intratumoral inflammatory response.
&(/*(1(352
1
5235,(7$5<,1)250$7,21
rabili
rability
ty
i
in 
in 
.
en less than
en less tha
stanc
stance.  Th
e.  Th
ation of nov
n of n
se of epigen
e of epige
munotherapy
unotherap
alal.
ethylat
hylatioion o
n
ng cancer (
ng cancer
n is reversi
is reversi
s targeting 
s targeting 
alignancies
alignancie
decitabine) 
decitabine)
a (vorinosta
(vorinosta
cititididine and
ine and
who had ext
ho had ex
).  Thoug
).  Thoug
this therapy
this therap
ed to variou
d to vario
ed 1 of 2
ed 1 of 2 ini
ry data reve
data rev
y
the other tw
he other tw
).  
).  
D-1 immun
1 immun
who receiv
who recei
hmer, 2012
hmer, 201
he results 
he results 
beco
bec me
me
is m

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
Azacitidine reactivates the production of tumor antigens, such as cancer testes antigens, 
that are found in lung cancer.
!
Azacitidine activates silenced effector cytokine genes in anergized T cells.  
Further support for using CC-486 in combination with pembrolizumab is the fact that epigenetic 
treatment of NSCLC cell lines has been found to increase expression of PD-1 and PD-L1.  Co-
administration of a PD-1 pathway inhibitor would shift the balance in favor of the immune-
enhancing effects of epigenetic modulators on T cells (Brahmer, 2013).  Thus, the combination 
of azacitidine and a PD-1 pathway inhibitor would mechanistically complement each other for 
the purpose of cancer treatment.
Current treatment options for metastatic NSCLC patients who have progressed on first-line 
therapy are limited.  The use of epigenetic modifying agents such as CC-486 to overcome
immune resistance mechanisms of tumors is an interesting strategy.  Here we propose to evaluate
the ability of CC-486 to sensitize tumor cells to PD-1 inhibition with pembrolizumab.  
To explore the hypothesized mechanism of CC-486 priming to pembrolizumab efficacy, and 
potentially identify biomarkers to predict patients that would benefit from this therapeutic 
regimen, tissue samples will be collected from patients pre-therapy and during therapy for 
cellular and molecular analyses. Submission of archival or fresh tumor tissue pre-therapy is 
mandatory. Blood, serum and saliva will also be collected. 
 
 
&(/*(1(35235,(7$5<,1)250$7,21
r 
-line
line
rcom
rcome
opose to ev
opose to ev
izuma
izu
b.b.
zumab effic
mab effi
rom thi
this the
s th
and during
durin
tumor tissu
mor tiss
5<
$5<
7$5
(7$
(7

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
2.
STUDY OBJECTIVES
2.1.
Primary Objective
The primary objective of the study is:
!
To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo based on PFS as measured using RECIST 1.1 criteria
2.2.
Secondary Objectives
The secondary objectives of the study are:
!
To estimate DCR of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo
!
To estimate OS of CC-486 plus pembrolizumab versus pembrolizumab plus placebo
!
To estimate ORR of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo
!
To evaluate safety and tolerability of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486
2.3.
Exploratory Objectives
The exploratory objectives of the study are:
!
To determine the preliminary efficacy (immune-related [ir] PFS, irDCR, irORR) of 
CC-486 plus pembrolizumab versus pembrolizumab plus placebo based on irRECIST
criteria 
!
To explore mechanism and biomarkers associated with efficacy of CC-486 plus 
pembrolizumab versus pembrolizumab plus placebo,
&(/*(1(35235,(7$5<,1)250$7,21
mab plus
mab plus
olizumab p
lizumab p
pembro
embrolizu
lizu
pembrolizu
pembrol
on the pharm
n the pharm
y efefficacy
ficacy
f
(i
ab
ab versus 
ver
ism and bi
m and b
versus pem
versus pe
( 3

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint
!
PFS measured as time from randomization to progression according to RECIST 1.1 
(based on Investigator assessment) 
3.2.
Secondary Endpoints
!
Number (%) of subjects with SD for ≥ 18 weeks, complete response (CR) or PR 
(DCR). 
!
Overall survival.
!
Number (%) of subjects who achieve an objective CR or PR (ORR).
!
Safety to include the incidence of treatment-emergent adverse events (TEAEs), 
serious TEAEs, Grade 3-4 TEAEs, TEAEs of special interest, and laboratory 
abnormalities and other safety parameters.
!
Plasma PK parameters such as maximum observed concentration (Cmax), area under 
the concentration-time curve (AUC), time to maximum concentration (Tmax), terminal 
half-life (t1/2), apparent total body clearance (CL/F) and apparent volume of
distribution (Vz/F) for CC-486.
3.3.
Exploratory Endpoint(s)
!
Exploratory efficacy as measured by irPFS, irDCR, and irORR based on Investigator 
assessment using irRECIST.
!
 
!
!
DNA analyses, gene expression and soluble factors in blood.
&(/*(1(
alyses, gen
yses, gen
35235,(7$5<,1)250$7,21
PR
R).)
events (
events TE
estst, and lab
and lab
concentrati
oncen
ximum con
ximum con
L/F) and ap
L/F) and ap
d by
d by irirPFS,
PFS,
23
523
35
( 3

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
4.
OVERALL STUDY DESIGN
4.1.
Study Design
This is a Phase 2, multicenter, international, randomized, placebo controlled, double-blind study
to assess the safety and efficacy of CC-486 and pembrolizumab combination therapy versus 
pembrolizumab plus placebo in previously treated subjects with locally advanced or metastatic 
NSCLC who have received only one prior platinum-based chemotherapy regimen.
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab as follows:
!
Arm A: CC-486 300 mg administered orally daily on days 1-14 plus pembrolizumab
200 mg administered as a 30-minute IV infusion on day 1 of a 21-day cycle 
!
Arm B: Placebo administered orally daily on days 1-14 plus pembrolizumab 200 mg
administered as a 30-minute IV infusion on day 1 of a 21-day cycle 
A safety analysis will be performed in the first 10 subjects in each arm after the last enrolled 
subject has completed 1 cycle of treatment.
Randomization will be stratified between treatment arms by:
!
Histology (non-squamous versus squamous)
The decision to discontinue a subject, which will not be delayed or refused by the Sponsor, 
remains the responsibility of the treating physician. However, prior to discontinuing a subject, 
the Investigator may contact the medical monitor and forward appropriate supporting documents 
for review and discussion.
The study will be conducted in compliance with the International Council on Harmonisation 
(ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good 
Clinical Practice (GCP) and applicable regulatory requirements.
Primary analysis will be conducted when 70 PFS events have occurred.
&(/*(1(35235,(7$5<,1)250$7,21
b or 
o
embro
mbrolizum
lizum
ay cycle
cycle
y
mbrolizuma
mbrolizum
y cycle
cycle
y
rm afafter th
ter th
f
t be delaye
t be delay
n. Howeve
n. Howev
tor and forw
tor and for
ance wi
nce w th
th
i
tht
h
r Registrati
r Registr
cable regul
cable regu
ducted when
ducted whe

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Figure 1:
Overall Study Design
4.2.
Study Duration 
Enrollment is expected to take approximately 12 months to complete.  Completion of active 
treatment and post-treatment follow-up is expected to take an additional 12 months.  The entire 
study is expected to last approximately 2 years.
4.3.
End of Trial
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, 
whichever is the later date.
&(/*(1(35235,(7$
12
12 months 
months 
xpecte
xpected to 
d to
years.
years.
either the d
ither the
r the date o
the date
condary
condary and
a
y
$7,21
date.
date.

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
5.
TABLE OF EVENTS
Table 2:
Table of Events
Screening
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-28 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Informed consent
X
Demographics
X
Prior cancer history
X
Prior cancer therapiesc
X
Complete medical history
X
Prior/ concomitant 
medication evaluationd
X (≤ 28d from 
screening)
Continuous, until 28 days after last dose
Prior/ concomitant 
procedures evaluatione
X (≤ 28d from 
screening)
Continuous, until 28 days after last dose
Inclusion/exclusion criteria
X
IRT registration
X
IRT randomization
Xf
Adverse event evaluation
Continuous after informed consent signature, until 30 days after discontinuation of either drug. See 
Section 11 for additional details on AE reporting timeframe
Physical examination 
(source documented only)
X
X
X
X
X
&(/*(
pri
prietet
nly)
ly)
*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
0$
0$
0$
0$
ent 
nt 
les
les
25
)2
1
)2
)2
)2
<
)2
<
5<
$ <
$5
7$
7$
7$
7$
7$
(7
5
C
5,
23
52
52
52
5
3
(
Continuous
Continuou
1(
X
*(
(/*
/

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-28 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Weight
X
X
X
X
X
Height
X
Vital signs
X
X
X
X
X
ECOG performance status
X
X
X
X
X
Hematology laboratoryg
X
X
X
X
X
X
X
Coagulationh
X
HBV and HCV serologies 
(HBsAg, HBeAg, HBsAb, 
HBeAb, HBcAb, HCVAb)
X
X
Chemistry laboratoryi
X
X
X
X
X
X
X
Lipid panelj
X
Every 4th
cycle
X
Thyroid test
X
X
Cycle 3 Day 
1 then every 
6 weeks
Urinalysisk
X
X
X
X
X
12-lead electrocardiogram
X
X
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet
7,2
0$
0$
0$
0$
1
50
2
X
1)
,1
<
5<
$ <
X
$5
7$
7$
7$
7$
7$
(7
5
X
35
2 5
23
52
35
(
5
X
(1
X
*(
/*
/*
/*
/*

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up Period
Day
-28 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Serum β-hCG (for all 
FCBP)l
X
Serum or Urine β-hCG (for 
all FCBP)l
X
(w/in72 hours)
X
X
X
X
PK blood draws sampling
(See Section 6.5 for 
timepoints)
X
X
Tumor biopsy for 
Biomarker Analyses
X
(Mandatory –
archival or 
fresh tumor 
collection)
X
(Optional)
Blood for Biomarker DNA 
Analyses
X 
X
Blood for Biomarker RNA 
Analyses
X
X
X
Serum for Biomarker 
Analyses
X 
X
Xm
X
Saliva for Germline DNA 
Analysis
X
&(/*(
pri
prietet
*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
7,2
0$
Fo
Folll
0$
0$
0$
1
E
50
)2
1)
<
)
< ,
<
$5
7$
(7
2 5, 7
X
2
52
X
35
( 3
( 3
( 3
( 3
( 3
1(
*(

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-28 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Tumor evaluation 
(CT/MRI)
X 
RECIST 1.1 algorithm: Every 6 weeks (± 5 days) from randomization for the first 24 
weeks then every 9 weeks until disease progression (for exceptions refer to 
Section 6.4.3) or start of a new anticancer treatment, or withdrawal of consent
The irRECIST will be evaluated as exploratory efficacy assessment. For additional 
details, see Sections 6.4.2 , 6.4.3 and Appendix B, Section 19.1
Bone Scan 
Only if clinically indicated
CT Scan of the Head or 
Brain MRI
X
Only if clinically indicated
Administer                    
CC-486/placebo
Daily on Days 1-14
Administer 
pembrolizumab
Xn
X
On Day 1 
only
IP accountability
X
X
X
X
Survival follow-up
Every 8 weeks 
(+/- 5 days)
Anticancer therapy since 
IP discontinuation
At every survival 
follow-up visit
Abbreviations:  β-hCG = beta human chorionic gonadotropin; C1D1 = Cycle 1 Day 1; CT = computed tomography; ECOG = Eastern Cooperative Oncology 
Group; EOT = End of Treatment; FCBP = females of child bearing potential; IP = investigational product; irRECIST = immune-related Response Evaluation 
Criteria in Solid Tumors; IRT = interactive response technology; MRI = magnetic resonance imaging; PK = pharmacokinetic; RECIST = Response Evaluation 
Criteria in Solid Tumors
a All visits have a ± 2-day window, except Cycle 1 Day 1 which must occur within 28 days from Informed Consent Form signature, and survival follow-up 
which has a ±5-day window.
&(/
pri
prietet
/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
7,2
0$
0$
0$
0$
1
E
50
)2
5 days) from
5 days) from
ease progre
se prog
nticancer tre
cancer tr
as explorat
as explor
6.4.2
6.4.2 , 6.4.
6.4
1)
y indicated
y indicated
$5
nly if clinica
ly if clinica
7$
Daily on D
Daily on 
,(
35
2 5
X
2
52
5
( 35
( 3
( 3
( 3
(1( 3
orionic gonad
rionic gonad
CBP = female
CBP = femal
nteractive res
teractive res
ndow, excep
ndow, excep
ow
ow.

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
b Cycle 1 Day 1 evaluations can be omitted if Screening evaluations are performed within 72 hours of Cycle 1 Day 1.
c Prior cancer therapies include surgery, radiation, systemic or any other therapy (eg, hormonal, locoregional) for the subject's cancer
d Prior/concomitant medication evaluation ≤28 days before screening through 28 days after last dose.
e Prior/concomitant procedures evaluation ≤28 days before screening through 28 days after last dose.
f Prior to receiving first dose.
g Hematology includes complete blood count (CBC) with differential, including but not limited to red blood cell (RBC) count, hemoglobin, hematocrit, white 
blood cell (WBC) count with differential (neutrophil count including lymphocyte, monocyte, eosinophil, basophil counts and bands), absolute neutrophil count 
(ANC), and platelet count. ANC should be measured with automated count where available.
h Coagulation tests, including prothrombin time (PT), partial thromboplastin time (PTT), activated partial thromboplastin time (aPTT) and international 
normalized ration (INR)
I Chemistry includes (but is not limited to) sodium, potassium, calcium, phosphorus,  chloride, magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, 
serum creatinine, fasting glucose, uric acid, albumin, total protein, alkaline phosphatase, lactate dehydrogenase, total bilirubin (indirect and direct), aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)
j Lipid Panel parameters include total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides
k Urinalysis (a urine dipstick may be used) at screening and D1 of each cycle if abnormal at baseline.
l Serum β-hCG (for all FCPB) performed at screening; remaining pregnancy tests may be serum or urine at the Investigator’s discretion. Pregnancy testing (for 
all FCPB) must be done within 72 hours prior to the first administration of IP and prior to dosing on Day 1 of every cycle.  If the serum screening pregnancy 
test is performed > 72 hours before first dose, a serum or urine pregnancy test should be performed (Investigator’s discretion).  The subject may not receive IP 
until the Investigator has verified that the result of the pregnancy test is negative.
m Day 1 of Cycle 3 and every third cycle thereafter (C6D1, C9D1, C12D1)
n On Cycle 1 Day 1, pembrolizumab will be administered after the 6 hour CC-486 PK sample collection. For all subsequent pembrolizumab administration, 
pembrolizumab will be co-administered with CC-486.
&(/*(1(35235,(7
pri
prietet
(7$5<,1)250$7,21
e Corpora
e Corpora
21
, hemoglobin
hemoglobi
and bands),
and bands),
astin t
stin time (aP
ime (
arbonate, blo
arbonate, blo
nase, total bi
se, total
m glutamic p
m glutamic p
glyce
glycerides
rides
e.
or urine at th
or urine a
sing on Day 
sing on Day 
erformed (In
erformed (In
PK sample c
PK sample c

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
6.
PROCEDURES
Any questions regarding the study should be directed to the Celgene medical monitor or 
designee. 
6.1.
Screening Period
Screening evaluations will be performed for all subjects to determine study eligibility. These 
evaluations must be completed within 28 days of first dosing unless noted below. Re-screening 
of patients is only allowed once per patient.
Waivers to the protocol will not be granted during the conduct of this trial, under any 
circumstances.
Safety laboratory analyses will be performed centrally. Decisions with respect to investigational 
product (IP) dosing can be made based on a local lab draw if the central lab results have not been 
received. Central labs should be drawn at all times specified within the protocol. Screening 
laboratory values must demonstrate subject eligibility, but may be repeated within the screening 
window if necessary.
The following will be performed at screening as specified in the Table of Events (Table 2), after
informed consent has been obtained:
!
Demographics 
!
Prior cancer history (including specific information regarding diagnosis, staging, and 
histology)
!
Prior cancer therapies: includes surgery, radiation, systemic or any other therapy for
the subject’s cancer
!
Complete medical history (all relevant medical conditions occurring ≥ 28 days before
Screening should be included)
!
Prior and concomitant medication evaluation (including those taken ≤28 days before
screening, except for those taken for cancer which are recorded as part of prior cancer 
therapy)
!
Prior and concomitant procedures (including all procedures occurring ≤ 28 days 
before screening)
!
Interactive response technology (IRT) for subject number 
!
Adverse event evaluation (begins after the subject signs the informed consent form 
[ICF])
!
Physical examination (source documented only), weight, height
!
Vital signs (including blood pressure, temperature, respiratory rate, and heart rate)
!
Eastern Cooperative Oncology Group (ECOG) performance status
&(/*(1(35235,(7$5<,1)250$7,21
ing
ng
to invest
investigi
b results hav
results ha
protocol.
otocol Sc
peated
eated wit
with
he Table of
he Table
informat
informatioio
surgery
rgery, rad
, ra
y (all
(all
y
releva
rele
l
ncluded)
ncluded)
tant m
tant medic
di
ept for thos
t for thos
nd concomi
nd concomi
re screening
re screenin
Interactive 
nteractive 
!
Advers
dvers
[ICF
[IC
!

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
Hematology panel: Complete blood count (CBC) with differential, including but not 
limited to red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell 
(WBC) count with differential (neutrophil count including lymphocyte, monocyte, 
eosinophil, basophil counts and bands), absolute neutrophil count (ANC), and platelet 
count.
!
Coagulation tests including, prothrombin time (PT), partial thromboplastin time 
(PTT), activated partial thromboplastin time (aPTT), international normalized ratio 
(INR).
!
Chemistry panel including, but not limited to sodium, potassium, calcium, 
phosphorus,  chloride, magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, 
serum creatinine, fasting glucose, uric acid, albumin, total protein, alkaline 
phosphatase, lactate dehydrogenase (LDH), total bilirubin (indirect and direct), 
aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), 
alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)
!
Lipid panel including total cholesterol, high-density lipoprotein, low-density 
lipoprotein, and triglycerides
!
Thyroid test
!
Hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies (hepatitis B surface 
antigen [HBsAg], hepatitis B e antigen [HBeAg], hepatitis B surface antibody 
[HBsAb], hepatitis B e antibody [HBeAb], hepatitis B core antibody [HBcAb], 
hepatitis C virus antibody [HCVAb]
!
Urinalysis (a urine dipstick may be used) at screening (and Day 1 of each cycle if 
abnormal at baseline).
!
12-lead electrocardiogram (ECG)
!
Pregnancy test is required for all female subjects of childbearing potential. Serum
beta subunit of human chorionic gonadotropin (β-hCG) pregnancy test will be 
performed at screening. Urine (or serum) pregnancy test will be performed to assess 
subject eligibility within 72 hours prior to the first administration of IP, if the serum 
pregnancy test did not already occur within 72 hours of dosing (negative results 
required for IP administration).
!
Submission of archival or newly obtained tumor biopsy specimen for biomarker 
analysis is mandatory.
!
Response assessment/tumor evaluation (see Section 6.4)
6.2.
Treatment Period
The subjects must start treatment within 28 days of signing the ICF. For all subsequent visits, an 
administrative window of ± 2 days is permitted.
Treatment cycles are 21 days in duration, and will occur as described in Section 8.2.
The following evaluations will be performed at the frequency specified in Table 2.  The 
evaluations should be performed prior to dosing on the visit day, unless otherwise specified:
&(/*(1(35235,(7$5<,1)250$7,21
or urea,
or urea,
e
d didirect),
rect),
i
e (AST/SG
(AST/S
ALT/S
ALT/SGPT
GP
tein, l
tein, low
ow-d
HCV) serolo
CV) serolo
Ag], hepat
g], hepa it
hepatit
hepatitis B
is B
used) at sc
sed) at sc
ECG)
CG)
ed for all fe
d for all f
n chorionic
n chorionic
ening. Urin
ening. Urin
ity y wi
with
th
i in 7
n 7
est did not a
est did not
or IP admi
or IP adm
f
missio
ission o
n of a
nalysis is m
alysis is m
Respons
Respons
.
Tr
Tr
The subje
The subje
dmini
dmini

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
IRT for subject randomization (prior to first dose)
!
Concomitant medications evaluation (continuously)
!
Concomitant procedures evaluation (continuously)
!
Adverse event evaluation (continuously)
!
Physical examination (source documented only) including weight
!
Vital signs: on-treatment vital sign measurements will be source documented only.  
However, if an abnormal (out of range) value is reported at any given visit, that
parameter should be collected in the case report form (CRF) at every subsequent
scheduled visit until it returns to normal, and as an AE if appropriate.
!
ECOG Performance status
!
Hematology panel
!
Chemistry panel
!
Lipid panel
!
Thyroid test
!
Urinalysis
!
Urine (or serum) pregnancy test (prior to dosing on Day 1 of each cycle)
!
PK sampling
!
Tumor biopsy for biomarker analyses [Optional, but strongly recommended]
!
Blood for biomarker analyses
!
Serum for biomarker analyses
!
Saliva for Germline DNA Analysis
!
Response assessment/tumor evaluation (see Section 6.4)
!
IP accountability
6.2.1.
End of Treatment
An end of treatment (EOT) evaluation should be performed for subjects who are withdrawn from
treatment for any reason as soon as possible after the decision to permanently discontinue
treatment has been made. Subjects must also be discontinued in the IRT system.
The following evaluations will be performed as specified in the Table 2:
!
Concomitant medications evaluation
!
Concomitant procedures evaluation
!
Adverse event evaluation (monitored through 30 days after the last dose of either 
study drug)
!
Physical examination including weight
&(/*(1(35235,(7$5<,1)250$7,21
entnt
sing on Day
ing on Da
es [Optiona
s [Option
ses
NA Analysi
A Analysi
ent/tumor e
ent/tumor 
ty
reatment
eatment
ment (EOT)
ment (EOT
any
any reason
reason
y
has been m
as been m
llo
llowing ev
wing ev
!
C
!

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
Vital signs
!
ECOG performance status
!
Hematology panel
!
Hepatitis B virus (HBV) and HCV serologies (HBsAg, HBeAg, HBsAb, HBeAb, 
HBcAb, HCVAb
!
Chemistry panel
!
Lipid panel
!
Urinalysis
!
12-lead ECG
!
Urine (or serum) β-hCG level for females of childbearing potential
!
Blood for biomarker analyses
!
Serum for biomarker analyses
!
Response assessment/tumor evaluation will be continued at the schedule defined in
Table 2, and does not need to be performed specifically for the EOT visit except as 
specified in Section 6.4.
!
IP accountability
6.3.
Follow-up Period
6.3.1.
Efficacy Follow-up
All subjects who discontinue treatment for reasons other than disease progression, start of new
anticancer therapy, or withdrawal of consent from the entire study will be followed for tumor
response assessments and subsequent anticancer therapies as specified in Section 6.4.
6.3.2.
Survival Follow-up
After the end of treatment (EOT) visit, all subjects will be followed every 8 weeks (± 5 days) for 
survival until withdrawal of consent, death, or lost to follow-up, whichever occurs first, or until 
the End of Trial. Subsequent anticancer therapies should be collected at the same schedule. New 
anticancer therapy includes (but is not limited to) any systemic or local medication, surgery, 
radiation, or any other therapy intended to treat the subject’s cancer.
Survival follow-up may be conducted by record review (including public records) and/or
telephone contact with the subject, family, or the subject’s treating physician.
6.4.
Response Assessments
Response assessments (tumor evaluations) should be performed at Screening within 28 days 
before the start of IPs, and every 6 weeks (± 5 days) from randomization for the first 24 weeks, 
then every 9 weeks thereafter until disease progression (for exceptions refer to Section 6.4.3), 
start of a new anticancer therapy, or withdrawal of consent from the entire study. Tumor 
assessments should also be performed at any time, if clinically indicated.  Subjects with 
&(/*(1(35235,(7$5<,1)250$7,21
ed at the sc
d at the s
ally for the
lly fo
for reasons 
or reason
onsent from
onsent 
ent ant
t a
ican
ican
up
up
t (
t EOT
OT) vi
wal
wal of
of
l
cons
ons
f
ubsequent a
ubsequent a
py
py i
y ncludes
nclude
any
ny other th
other th
y
follolow-up 
up
one contact
one contact
6.4.
.4.
R
Respon
Respon

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
historical tumor scans evaluable per RECIST 1.1 performed ≤ 28 days before the first dose need 
not repeat scans for the purposes of screening. Evaluation of response should be performed using 
RECIST 1.1 and irRECIST guidelines by Investigator assessment.  
6.4.1.
Assessment of Response According to RECIST Version 1.1
Response assessments include computed tomography (CT) scan or MRI.  The regions to be 
imaged are the chest, upper abdomen including whole liver and kidney and, if clinically 
indicated, pelvis. The pelvis scan should be performed only with MRI unless CT is the local 
standard of care at the site. In case of metastases to other organs not covered with these scans, 
the regions need to be included in the scans as well. If brain metastases are documented at 
baseline, brain imaging should be continued throughout the study. Bone scans will only be 
performed at baseline if clinically indicated. If at baseline, the bone scan is suggestive of bone 
lesions, CT or MRI will be used both at baseline and subsequent scans. Bone scans during the 
trial will only be performed if clinically indicated and if suggestive of new lesions, a CT or MRI 
will be performed to confirm the new lesion. Any skeletal lesions identified at baseline should be 
followed at the same schedule. The same mode of imaging for lesion evaluation at Screening 
must be used consistently throughout the study. Adherence to the planned imaging schedule is 
critical regardless of dose delays or unscheduled or missed assessments; scans must follow the 
calendar and not be adjusted for delays in treatment.
The CT imaging should include contrast unless medically contraindicated. Conventional CT 
should be performed with contiguous cuts of 5 mm or less in slice thickness. Spiral CT should be 
performed by use of a 5 mm contiguous reconstruction algorithm.
All subjects with evidence of objective tumor response (CR or PR) should have the response 
confirmed with repeat assessments at the next scheduled scan, but after no less than 4 weeks.  
6.4.2.
Assessment of Response According to irRECIST
Evaluation of response will also be performed using irRECIST guidelines as an exploratory 
assessment.  Additional details and definitions of irRECIST are found in Appendix B in Section
19.2.
6.4.3.
Assessment of Disease and Treatment after Initial Radiologic Progression
Immunotherapeutic agents such as pembrolizumab may produce antitumor effects by 
potentiating endogenous cancer-specific immune responses.  The response patterns seen with 
such an approach may extend beyond the typical time course of responses seen with cytotoxic 
agents, and can manifest as a clinical response after an initial increase in tumor burden or even 
the appearance of new lesions.  
If radiologic imaging shows PD by RECIST 1.1, tumor assessment should be repeated ≥4 weeks 
later in order to confirm PD (per irRECIST) with the option of continuing treatment per below 
while awaiting radiologic confirmation of progression.  If repeat imaging shows a reduction in 
the tumor burden compared to the initial scan demonstrating PD, treatment may be continued as 
per treatment calendar. A separate informed consent will be provided.  If repeat imaging 
confirms progressive disease, subjects will be discontinued from study therapy (exception noted
in Table 3).  In determining whether or not the tumor burden has increased or decreased, 
&(/*(1(35235,(7$5<,1)250$7,21
s, 
s, 
t
y be
y be
ve of bone 
ve of bone
ans during t
ns during 
ions, a CT 
a CT
d at baselin
at baselin
aluat
uatioion at 
n
nned imagi
nned imagi
ment
me s; scan
s; scan
contraindica
ntraindi
ss in slice t
s in slice
on algorithm
on algorithm
ponse (C
ponse (CR
scheduled 
scheduled 
cording to 
cording to
perform
erformed u
ed
d definit
d definitioi
f Disease a
f Disea
gents such 
gents suc
genous canc
enous canc
ch may
ch may ext
ext
y
can manifes
can manife
rance of ne
ce of ne
iolologigic ima
c im
er in order 
r in order 
while awa
while awa
he tum
e tum

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Investigators should consider all target lesions as well as non-target lesions. Refer to Appendix B
for additional information.
When feasible, subjects should not be discontinued until progression is confirmed; however, the 
decision to continue study treatment after the 1st evidence of disease progression is at the 
Investigator’s discretion based on the clinical status of the subject as described in Table 3.  
Subjects may receive study treatment while waiting for confirmation of PD if they are clinically 
stable as defined by the following criteria:
!
Absence of signs and symptoms indicating disease progression
!
No decline in ECOG performance status
!
Absence of rapid progression of disease
!
Absence of progressive tumor at critical anatomical sites (eg, cord compression) 
requiring urgent alternative medical intervention
Table 3:
Imaging and Treatment after Site-Assessed 1st Radiologic Evidence of PD
Clinically Stable
Clinically Unstable
Imaging
Treatment
Imaging
Treatment
Site based 
assessment 
indicates PD
Repeat imaging at 
≥4 weeks at site to 
confirm PD
May continue 
study treatment at 
the Investigator’s 
discretion while 
awaiting 
confirmatory scan 
by site
Repeat imaging at 
≥4 weeks to 
confirm PD per 
physician 
discretion only
Discontinue 
treatment
Repeat scan 
confirms PD
No additional 
imaging required
Exceptions as per 
note*
Discontinue
treatment
Exceptions as per 
note*
No additional 
imaging required
N/A
Repeat scan shows 
SD, PR or CR
Continue regularly 
scheduled imaging 
assessments
Continue study 
treatment at the 
Investigator’s 
discretion
Continue regularly 
scheduled imaging 
assessments
May restart study 
treatment if 
condition has 
improved and/or 
clinically stable 
per Investigator’s 
discretion
* Note:  If progression is confirmed per irRECIST, the subject remains clinically stable and per the Principal 
Investigator is achieving extraordinary clinical benefit, the Principal Investigator may discuss with the Sponsor to 
consider a potential exception.
6.5.
Pharmacokinetics
At specific sites, for the first 10-12 subjects randomized to each Arm, mandatory 
pharmacokinetics will be collected. Blood samples for CC-486 PK assessment will be collected 
on Day 1 of Cycle 1 and Cycle 2 prior to the dose administration of CC-486/placebo, known as 
predose, and over the 8-hour period following each dose administration of CC-486/placebo at 
mpressio
mpression)
n
ogic Eviden
gic Evide
Clinically 
Clinically
1)
Imaging
a
,1
lele
atory scan
tory scan
e
Repeat imag
Repeat ima
≥4 weeks
4 week
confirm
confir
phy
ph
d
5<
7$
er 
Discontinue
iscontinue
treatment
reatment
Excep
xcep
not
not
5,
52
 regularly
regularly
uled imagin
uled ima
essments
essme
5
*(
5
*(
*(
*(
5
progression i
gression
igator 
igato is achi
s achi
sider a poten
sider a poten
6.5.
6.
sp

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose (see Table 4).  These samples will be 
analyzed centrally.
Table 4:
Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase
Nominal Times
Acceptable Deviation Window
Predose
≤ 60 min
0.25 hr
± 3 min
0.5 hr
± 3 min
1 hr
± 3 min
1.5 hr
± 3 min
2 hr
± 3 min
2.5 hr
± 3 min
3 hr
± 3 min
3.5 hr
± 3 min
4 hr
± 3 min
6 hr
± 20 min
8 hr
± 20 min
6.6.
Biomarkers
Tumor, blood and serum will be collected to explore the hypothesized mechanism of CC-486 
priming to pembrolizumab efficacy, and potentially identify biomarkers to predict patients that 
would benefit from this therapeutic regimen. Fresh tumor biopsy is the preferred tissue for these 
analyses; however archival formalin fixed, paraffin embedded (FFPE) blocks may be provided 
instead. Archival or fresh tumor tissue is mandatory at screening, but it is optional at Cycle 2 
Day 14 -/+ 7 days. Blood, serum and saliva will also be collected at time point detailed in the 
schedule of events.
Details regarding the collection, storage, and shipment of the samples are provided in the 
Laboratory Manual. A separate consent will be provided.
6.7.
12-lead Electrocardiogram
Triplicate 12-lead ECGs will be recorded at screening and EOT and will be assessed locally. 
ECGs may be done more frequently and/or additional cardiac work-up may be performed, if 
clinically indicated by the investigator. The 12-lead ECGs (12-lead at 25 mm/sec reporting 
rhythm, ventricular rate, PR-interval, QRS complex, QT interval, and QTc interval) will be 
performed after the subject has been in the supine position for at least 5 minutes.
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
25
min
min
)2
± 3 min
± 3 min
1)
± 3 mi
3 mi
,1
± ±
<
5<
$5
(7$
to explore t
to explore 
d potentiall
potentia
egimen. Fr
egimen. 
lin fixed, p
lin fixed, 
r tissue
tissue isis
erum
erum and sa
and
collect
collectioion
al. A separa
A separa
2-lead E
lead E
te 12
te 12-lead E
lead 
s m
s may be d
ay be 
inically ind
inically ind
rhy
hyth
y m,
m, ve
v
erform
erform

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
7.
STUDY POPULATION
7.1.
Number of Subjects and Sites
A total of approximately 90 adult subjects with locally advanced or metastatic NSCLC who have 
been treated with one prior platinum-based chemotherapy regimen will be randomized. The 
study will be conducted at sites globally.
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Subject is ≥ 18 years of age at the time of signing the informed consent form.
2. Subject has histologically or cytologically confirmed squamous or non-squamous 
NSCLC.
3. Subject has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] 
Staging Manual, 7th edition [Edge, 2009]) and was pretreated with only 1 prior systemic
platinum based chemotherapy.
4. Subject has provided a formalin fixed tumor tissue sample from a biopsy of a tumor 
lesion either at the time of or after the diagnosis of metastatic disease has been made 
AND from a site not previously irradiated to assess for PD-L1 status. Fine needle 
aspirates, endobronchial ultrasound (EBUS) or cell blocks are not acceptable. Needle or 
excisional biopsies, or resected tissue is required.  Archival tissue may be acceptable.
Submission of formalin-fixed paraffin embedded tumor tissue sample blocks are 
preferred; if submitting unstained slides, the slides should be freshly cut and submitted to 
the testing laboratory within 14 days from site slide sectioning date otherwise a new 
specimen will be requested.
5. Subject has radiographically-documented measurable disease, as per RECIST 1.1.
6. Subject has an ECOG performance status of 0 to 1.
7. Subject has adequate organ functions, evidenced by the following:
a.
AST (SGOT), ALT (SGPT) ≤ 2.5 x upper limit of normal range (ULN), or ≤ 5 x ULN 
range if liver metastasis present
b. Total bilirubin ≤ 1.5 x ULN
c.
Serum creatinine ≤ 1.5 x ULN
d. Potassium within normal range, or correctable with supplements
8. Subject has adequate bone marrow function, evidenced by the following:
a.
Absolute neutrophil count ≥ 1.5 x 109 cells/L
b. Platelets ≥ 100 x 109 cells/L 
c.
Hemoglobin ≥ 9 g/dL
d. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 x ULN unless 
subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic 
range of intended use of anticoagulants
&(/*(1(35235,(7$5<,1)250$7,21
m.
squamous
squamou
ee on Canc
ee on Can
d with
with onl
mple fro
mple from
metastati
etastatic
ess
ess fo
for PD
r PD
or cell bloc
or cell bl
equired.  Ar
quired.  A
embedded 
embedded 
ides, the sli
des, the sl
days from si
ays from
lly
lly-docum
docum
performan
performan
uate organ f
uate orga
OT), ALT (
OT), ALT
f liver meta
f liver meta
l bili
bili
l
rubin
rubin
i
erum
erum c
m reat
rea
Potassi
Potassiui
Subject h
Subject
a.a
A
b.b

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
e.
Activated partial thromboplastin time (aPTT) ≤1.5 x ULN unless subject is receiving 
anticoagulant therapy as long as PT or PTT is within therapeutic range of intended 
use of anticoagulants
9. Female of childbearing potential (FCBP) (defined as a sexually mature woman who 1) 
has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral 
oophorectomy (the surgical removal of both ovaries) or, 2) if ≥ 45 years old has not been 
naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any 
time during the preceding 24 consecutive months)) must:
a.
Have two negative pregnancy tests as verified by the Investigator prior to starting 
study therapy. She must agree to ongoing pregnancy testing during the course of the 
study, and after end of study treatment. This applies even if the subject practices true 
abstinence* from heterosexual contact.
b. Either commit to true abstinence* from heterosexual contact (which must be 
reviewed on a monthly basis) or agree to use, and be able to comply with two 
effective methods of contraception without interruption, 28 days prior to starting IP, 
during the study therapy (including dose interruptions), and for 120 days after 
discontinuation (or longer if required by local requirements) of study therapy. The 
two methods of contraception can either be two barrier methods or a barrier method 
plus a hormonal method to prevent pregnancy.
10. Male subjects must practice true abstinence* (which must be reviewed on a monthly 
basis) or agree to the use a condom during sexual contact with a pregnant female or a 
female of childbearing potential while participating in the study, during dose 
interruptions and for at least 3 months following investigational product discontinuation 
(or longer if required by local requirements), even if he has undergone a successful 
vasectomy. 
* True abstinence is acceptable when this is in line with the preferred and usual lifestyle 
of the subject. Note: Periodic abstinence (eg, calendar, ovulation, symptothermal, post-
ovulation  methods) and withdrawal are not acceptable methods of contraception.
11. Subject is willing to adhere to the study visit schedule and other protocol requirements.
12. Subject understands and voluntarily signs an informed consent document prior to any 
study related assessments/procedures are conducted.
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subject with non-squamous histology has known or unknown sensitizing EGFR and/or 
positive ALK mutation.
Note: Subjects with squamous histology and unknown EGFR and ALK mutational 
status are eligible.
2. Subject has received more than one line of therapy for stage IIIB or IV disease
3. Subject has been previously treated with azacitidine (any formulation), decitabine, or any 
other hypomethylating agent.
&(/*(1(35235,(7$5<,1)250$7,21
arting
arting
e of the
of the
actices true
actices true
which
whic must 
mus
mply
mply wi
wi
y
th
th
i
t
days prior to
ys prio
nd for 
d for 120 d
120 d
ments) of stu
ents) of st
ier method
er m
ich must b
ch must
xual contac
xual contac
cipat
ipa ing in
ing in
ollo
llowing in
wing i
ements), ev
ments), ev
le when thi
le when
dic ab
a stininen
d wi
with
th
i drawa
drawa
 adhere to 
adhere to
ands and 
ands and v
asses
assessmen
smen
clusion C
clusion 
nce of any o
ce of any 
Subject
Subject w
posi
posititi
i v

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
4. Subject has received prior therapy with any other anti-PD-1, or PD-L1 or PD-L2 agent or 
an antibody targeting other immuno-regulatory receptors or mechanism, including 
participation in any other pembrolizumab trial and treatment with pembrolizumab.
a.
Examples of such antibodies include (but are not limited to) antibodies against 
indoleamine 2,3-dioxygenase (IDO), PD-L1, IL-2R, glucocorticoid-induced 
tumor necrosis factor receptor (GITR).
5. Subject has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who 
has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to agents 
administered more than 4 weeks earlier.
6. Subject is currently participating and receiving study therapy or has participated in a 
study of an investigational agent and received study therapy or used an investigational 
device within 4 weeks prior to administration of pembrolizumab and CC-486
7. Subject has previous severe hypersensitivity reaction to another monoclonal antibody 
(mAb).
8. Subject has a known or suspected hypersensitivity to azacitidine, mannitol, or any other 
ingredient used in the manufacture of CC-486 (see the Azacitidine IB).
9. Subject has had radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks 
prior to starting IP, and/or from whom ≥ 30% of the bone marrow was irradiated.
10. Subject has received radiation therapy to the lung that is > 30 Gy within 6 months of the 
first dose of trial treatment
11. Subject has received a live-virus vaccination within 30 days of planned treatment start. 
Seasonal flu vaccines that do not contain live virus are permitted.
12. Subject has not recovered from the acute toxic effects of prior anticancer therapy, 
radiation, or major surgery/significant trauma.
13. Subject has an active infection requiring therapy.
14. Subject has had an allogenetic tissue/solid organ transplant.
15. Subject has active autoimmune disease that has required systemic treatment within the 
past 2 years (eg, with use of disease modifying agents, corticosteroids or 
immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic 
corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not 
considered a form of systemic treatment.
16. Subject has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is 
defined as a known positive HBsAg result.  Active Hepatitis C is defined by a known 
positive Hep C Ab result and known quantitative HCV ribonucleic acid (RNA) results 
greater than the lower limits of detection of the assay.
17. Subject has had any other malignancy within 5 years prior to randomization, with the 
exception of adequately treated in situ carcinoma of the cervix, uterus, or non-
melanomatous skin cancer (all treatment of which should have been completed 6 months 
prior to enrollment).
d in a
d in a
tigat
igatioional
nal
486
486
oclonal ant
oclonal an
ne, m
ne, manni
anniti
cit
ci idine IB)
ine IB
radiat
radiatioi n 
bone marr
bone marr
ng that is > 
ng that is >
tion wi
n within
thin
i
ain live vir
ain live vir
e acute tox
e acute tox
nificant tra
nificant tra
tion requir
n requ
ogenet
ogenetic t
ic tisi
autoimmu
autoim
g, wi
w th
th
i
use e
h
pressive 
essive dru
dr
roi
roid repl
d replac
ac
ered a form
red a form
ubject has k
ect has k
defined as
defined as
posi
posititi
i ve
ve
grea
grea
17.
17.

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
18. Subject has a history of inflammatory bowel disease (eg, Crohn’s disease, ulcerative 
colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other 
gastrointestinal disorder or defect that would interfere with the absorption, distribution, 
metabolism, or excretion of the IP and/or predispose the subject to an increased risk of 
gastrointestinal toxicity.
19. Subject has persistent diarrhea or clinically significant malabsorption syndrome or known 
sub-acute bowel obstruction ≥ Grade 2, despite medical management
20. Subject has significant active cardiac disease within the previous 6 months including 
unstable angina or angina requiring surgical or medical intervention, significant cardiac 
arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart 
failure.
21. Subject has history of interstitial lung disease (ILD) OR a history of pneumonitis that has 
required oral or IV steroids. Subjects whose pneumonitis was solely as a result of 
radiation therapy for their NSCLC would not be excluded from the study unless they 
received oral/IV steroids to manage the pneumonitis.
22. Subject has a known history or current diagnosis of human immunodeficiency virus 
(HIV) infection, regardless of treatment status.
23. Subject has any other concurrent severe and/or uncontrolled medical condition that 
would, in the Investigator’s judgment, contraindicate patient participation in the clinical 
study (eg, chronic pancreatitis, etc.).
24. Subject with uncontrolled or symptomatic central nervous system (CNS) metastases
and/or carcinomatous meningitis
!
Subjects with controlled and asymptomatic CNS metastases may participate in this 
trial. The patient must have completed any prior treatment for CNS metastases (must 
include radiotherapy and/or surgery) ≥ 28 days (≥ 14 days for stereotactic 
radiosurgery). Patients must not be receiving corticosteroids for brain metastases.
25. Subject has not recovered from the acute toxic effects (Common Terminology Criteria for 
Adverse Events [CTCAE] grade ≤ 1) of prior anticancer therapy, radiation, or major 
surgery/significant trauma (except alopecia or other toxicities not considered a safety risk 
for the subject at the Investigator’s discretion).
26. Subject has an impaired ability to swallow oral medication.
27. Subject is pregnant or breast feeding.
28. Subject has any condition that confounds the ability to interpret data from the study.
29. Subject is or has an immediate family member (spouse or children) who is investigational 
site or sponsor staff directly involved with this trial, unless prospective Institutional 
Review Board (IRB) approval (by chair or designee) is given allowing exception to this 
criterion for a specific subject.
&(/*(1(35235,(7$5<,1)250$7,21
rdiac
diac
art 
umo
umonit
nitis tha
is th
s a result of
s a result o
study unle
study unle
mmunodef
munodef
trolled med
trolled me
ate patient 
ate patient 
entral
entral nerv
nerv
l
ymptomatic
mptomatic
om
ompleted a
pleted
m
or surgery
or surge
)y
must not be
ust not b
m
red fro
ed from 
m th
t
TCAE] grad
CAE] gra
nt trauma (e
nt trauma
at the I
at the Inve
n
as an impair
as an impai
ct is pregna
ct is pregn
ubject has a
ect has a
9.9. Subject 
Subject
sisite or
te o
i
Re
Re

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Products
Subjects will receive CC-486 plus pembrolizumab or pembrolizumab plus placebo during the 
study.  CC-486 and matching placebo will be double blind whereas pembrolizumab will be open 
label. CC-486 and pembrolizumab are designated as IPs.  All IPs must be stored in an area free 
of environmental extremes and a secured area to prevent unauthorized access, as directed on the 
package label. A temperature log must be maintained.
8.1.1.
CC-486 (Oral Azacitidine)/Placebo
The study sponsor, Celgene Corporation will supply CC-486 and placebo 150 and 200-mg 
tablets for oral administration. Sufficient quantities of IP will be supplied by Celgene and should 
be stored as directed on the label. All tablets will be packaged in blister packs. Each tablet is 
formulated using excipients that are generally regarded as safe and used in marketed drug 
products.  A list of excipients included in the formulations is provided in the azacitidine IB.  
8.1.2.
Pembrolizumab
Pembrolizumab (50 mg lyophilized powder in single-use vial for reconstitution) for IV 
administration will be sourced by the study sponsor (Celgene Corporation) from 
 
 and labeled for clinical trial use.  Sufficient quantities of IP will be supplied by 
Celgene and should be stored as directed on the label.  Pembrolizumab will be administered in 
the clinic.
The Pharmacy Manual contains specific instructions for pembrolizumab dose calculation, 
reconstitution, preparation of the infusion fluid, and administration.
8.2.
Treatment Administration and Schedule
Subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or pembrolizumab plus 
placebo. CC-486/placebo will be administered at a dose of 300 mg orally daily on days 1-14 of a 
21-day cycle.
During scheduled site visits the subjects must arrive to the clinic in the fasting state (ie, no food 
or drink [except water] for approximately 8 - 10 hours) for all predose safety laboratory 
evaluations. Dose administration should take place after all scheduled predose safety assessments 
are completed.
Subjects will ingest CC-486/placebo with approximately 240 mL (8 ounces) of room temperature 
water.  CC-486/placebo may be taken on an empty stomach or with food (a light breakfast or 
meal of up to approximately 600 calories).
If following CC-486/placebo administration an emesis event occurs, subjects should not take 
additional drug on that same day. It is recommended that the subject receives an antiemetic 30 
minutes prior to all subsequent CC-486 doses.
Pembrolizumab will be administered as a 30-minute IV infusion at a dose of 200 mg (4 x 50 mg 
vials) on Day 1 of a 21-day cycle. Sites should make every effort to target infusion timing to be 
&(/*(1(35235,(7$5<,1)250$7,21
the
d 200-
200-mg
mg
Celgene an
elgene an
cks. Each t
cks. Each t
in markete
n mark
d in the aza
d in the aza
al fo
for recon
r recon
gene Corpo
ene Cor
nt quant
nt quantititiei
el.  Pembro
el.  Pembr
tructions fo
tructions fo
fluid, and
fluid, and
tration a
ration 
1 to receive
 to receive
ll be admin
ll be adm
e visi
visits the 
ts th
i
water] for ap
ater] for ap
se adminis
se admi
ed.
ed.
s will inges
 will inge
.  CC
.  CC-486
-486/
eal of up to
eal of up to
If fof llow
didititi
i

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
as close to 30 minutes as possible. However, given the variability of infusion pumps from site to 
site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time of 24-40 minutes).
Pembrolizumab should be co-administered with CC-486.
For subjects enrolled in the PK population, the treatment administration on PK days (i.e., Day 1 
of Cycle 1 and Cycle 2) is described below:
!
After performing the required overnight fast, taking antiemetic premedication with 
240 mL of water for nausea and vomiting (eg, ondansetron), and completing the 
required predose assessments (including the predose PK sample), subjects will ingest 
CC-486/placebo with 240 mL of room temperature water in the clinic approximately 
30 minutes after antiemetic administration on each PK dosing day.  Each dose of   
CC-486/placebo should be given at approximately the same time each day.  The exact 
date and time of dosing will be recorded in the source documents and appropriate 
CRF.
!
On Day 1 of Cycle 1 only, pembrolizumab will be administered as described above, 
but administration will start after the 6 hour CC-486 PK sample collection time-point.
Dietary restrictions on PK days (i.e., Day 1 of Cycle 1 and Cycle 2): 
!
Subjects should be instructed to limit their coffee intake to one 8-ounce cup of black 
coffee (no cream or sugar) and to not consume alcohol, tea, chocolate, or cola 
beverages within 2 hours prior to collecting PK samples.
!
Subjects should not ingest food for a minimum of 8 hours prior and 2 hours after CC-
486/placebo is administered.  Water can be allowed as desired except for 1 hour 
before and after CC-486/placebo administration.  The only water permitted in the 1-
hour period before CC-486/placebo administration is the 240 mL of water for 
antiemetic ingestion.
8.2.1.
Dose Adjustment Guidelines
8.2.1.1.
CC-486 (oral azacitidine)/Placebo
For CC-486/placebo, a maximum of 1 dose reduction will be allowed from the original dose (eg, 
patients can dose reduce from 300 mg/placebo oral daily dose to 200 mg/placebo oral daily 
dose). Re-escalation to the higher dose is not permitted. If a subject requires more than 1 dose 
reduction for CC-486/placebo, they will be discontinued from CC-486/placebo, however, they 
may continue to receive pembrolizumab (and conversely, subjects who discontinue 
pembrolizumab may continue to receive CC-486/placebo) but must continue to undergo all 
safety and efficacy assessments as per Table 2.
CC-486/placebo may be withheld for up to 7 days between the end of 1 cycle and the start of the 
next cycle to allow hematologic criteria to recover sufficiently for the next cycle to begin.
The maximum number of days that a dose may be withheld without requiring a dose reduction is 
7 days.
The maximum number of days that a dose may be withheld due to unacceptable toxicity before a 
subject is permanently discontinued from CC-486 is 14 days.  For the purposes of dose 
adjustments, unacceptable toxicity will be defined as any AE that is deemed by the Investigator 
&(/*(1(35235,(7$5<,1)250$7,21
gest 
st
mately
mately
e of  
of  
y.  The exa
y.  The exa
appropriate
ppropriate
d as describ
as describ
mple co
mple collect
lle
:
take to one
ake to
cohol, tea, 
cohol, tea,
K samples.
K samples.
imum of 8 h
mum of 
n be allo
n be allowe
w
ministrati
ministratio
bo adminis
bo adminis
elines
lines
itidine)
idine)/P
/Pl
ximum of 
imum of 
e fro
 fr m 300
30
to the high
o the hig
486
86/placeb
/placeb
to receive p
o receive
mab may co
mab may c
d efficacy 
fficacy
86/
86 plpl
/ acebo
aceb
ext cy
ext cycle to
cle to
The m
The max
a
day

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
to be related to CC-486/placebo that poses a medical risk or substantial discomfort to the subject 
including, but not limited to, Grade 3 or 4 hematologic or non-hematologic toxicity. Subjects 
should be discontinued after the 3rd episode.
See Section 8.2.1.2 and Table 6 for dose modification guidelines for pembrolizumab drug-related 
adverse events for overlapping toxicity events for all IPs.
Please refer to Table 5 for the Dose Adjustment Guidelines.
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity
Toxicity
Recommendation
Grade 2 hematologic toxicity causing delay to the 
planned start of a Cycle
Absolute Neutrophil Count (ANC) < 1.5 x 109/L
Platelets < 75 x 109/L
Hold CC-486/placebo until ANC & Platelets 
≤ Grade 1
Delay ≤ 7 days, resume CC-486/placebo at same 
dose
Delay 8 – 14 days, reduce CC-486/placebo by 100 
mg
Delay > 14 days, permanently discontinue from 
study
Grade 3 neutropenia or thrombocytopenia causing 
delay to the planned start of a Cycle ANC 0.5-0.99 
x 109/L
Platelets 25-49 x 109/L
Hold CC-486/placebo until ANC & Platelets 
recover to ≤Grade 1 (ANC ≥ 1.5 x 109/L, Platelets 
≥ 75 x 109/L)
Recovery in ≤ 7 days, resume CC-486/placebo at 
same dose
Recovery in 8–14 days, reduce CC-486/placebo by 
100 mg
No recovery by 14 days, permanently discontinue 
from study
Grade 4 neutropenia or thrombocytopenia causing 
delay to the planned start of a Cycle
ANC < 0.5 x 109/L
Platelets < 25 x 109/L
For ANC < 0.5 x 109/L
The initiation of G-CSF is left at the Investigator’s 
discretion. If initiated administer G-CSF per 
institutional practice or package insert and continue 
until ANC recovers to ≥ 2.0 x 109/L
Hold CC-486/placebo until ANC & Platelets 
recover to ≤Grade 1
(ANC ≥ 1.5 x 109/L, Platelets ≥ 75 x 109/L)
Recovery in ≤ 7 days, reduce CC-486/placebo by 
100 mg
No recovery by 7 days, permanently discontinue 
from study
&(/*(1(3523
enia causing
ia causin
e
CSF is left at
CSF is left a
ated 
ated admini
admini
actice or pac
ctice or pa
ecovers to
covers to ≥
235,(7$5<,1)250$7,21
$7
$7
$7
elets
elet
plac
placeb
ebo at s
CC
CC-486/
486/pla
pla
/
rmanently d
manently d
0$
6/6/placebo
placebo
/
un
≤Grade 1 
Grade 1
109/L)
/L)
covery in
covery in ≤ 
ame dose
ame dose
Recov
Recoverer
100 m
100 m
N
<
5,
23
/*

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity (Continued)
Toxicity
Recommendation
Grade 3 or 4 Nausea or Vomiting
Grade 3 or 4 Diarrhea
Grade 3 or 4 Fatigue/Asthenia
Hold until resolution to ≤ Grade 1 and provide 
optimal medical management
If response ≤72 hours (3 days), and recovery ≤ 7 
days, reintroduce CC-486/placebo at 200 mg
If event recurs after re-challenge at 200 mg, 
discontinue CC-486/placebo
If no recovery by 7 days, discontinue CC-
486/placebo
Grade 3 or 4 any other non-hematologic toxicity
Hold until resolution to ≤ Grade 1 and provide 
optimal medical management
If recovery ≤ 7 days, reintroduce CC-486/placebo 
at 200 mg
If event recurs after re-challenge at 200 mg, 
discontinue CC-486/placebo
If no recovery by 7 days, discontinue CC-
486/placebo
Renal dysfunction - For any unexplained 
reductions in serum bicarbonate levels to < 20 
mEq/L or unexplained elevations of BUN and/or 
serum creatinine (> 20%) from baseline
Hold until resolution to ≤ baseline level (+/- 20%) 
Reduce CC-486 dose in the next cycle of treatment 
to the next lower dose level 
If similar unexplained renal and/or electrolyte 
disturbances subsequently persist or recur, 
discontinue CC-486
ANC = absolute neutrophil count; ASCO = American Society of Clinical Oncology; BUN = blood urea nitrogen; ESMO =
European Society for Medical Oncology; G-CSF = granulocyte colony stimulating factor.
Note: The initiation of G-CSF is left at the Investigator’s discretion.
Note: Granulocyte colony stimulating factor (G-CSF) should only be utilized in accordance to ASCO or ESMO 
recommendations.
Note: If Grade 3 or 4 neutropenia associated with fever or Grade ≥ 3 thrombocytopenia with clinically significant bleeding 
occurs at any time, the dose adjustment guidelines for Grade 4 hematological toxicity should be enacted.
Note: If neutropenia is associated with fever and severe diarrhea, subject should be managed appropriately according to the local 
practice. In case of recurrence of the diarrhea with neutropenia and fever, the continuation of the subject in the study should be 
discussed on a case-by-case basis with the sponsor’s study monitor.
8.2.1.2.
Pembrolizumab
Adverse events associated with pembrolizumab exposure may represent an immunologic 
etiology.  These adverse events may occur shortly after the first dose or several months after the 
last dose of treatment. Pembrolizumab must be withheld for drug-related toxicities and severe or 
life-threatening AEs as per Table 6 below. Dose reductions are not permitted for pembrolizumab.
&(/
th
th
(/*(1(35235,(7$5<,1)250$7,21
$7
nd provide
nd provide
uce CC
uce C -486/
-486
challenge at
challenge 
placebo
placebo
7 days, dis
7 days, dis
0
l resolution 
resolution
e CC
CC-486 d
486 
he next low
he next lo
If similar un
If similar u
disturban
disturba
discon
discon
5<
5,
5
Society of Clin
ociety of Clin
= granulocyte c
granulocyte
igator
igator’s discre
’s d
G-CSF) should
CSF) shoul
ated with feve
ed with fev
ent guidelines
ent guideli
with fever and 
h fever and 
of the diarrhe
of the diarrh
 basis with th
basis with
rolizumab
rolizumab
ntnts s associat
associat
These adve
hese adv
se of treatm
se of treatm
reatening
reatening
h

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events
Toxicity
Hold 
Treatment 
For Grade
Timing for Restarting 
Treatment
Treatment Discontinuation
Diarrhea/Colitis
2-3
Toxicity resolves to 
Grade 0-1.
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
AST, ALT, or 
Increased Bilirubin
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose.
3-4
Permanently discontinue
(see exception below)1
Permanently discontinue
Type 1 diabetes 
mellitus (T1DM), if 
new onset, or 
Hyperglycemia
T1DM or
3-4
Hold pembrolizumab for 
new onset Type 1 
diabetes mellitus or 
Grade 3-4 hyperglycemia 
associated with evidence 
of beta cell failure.
Resume pembrolizumab when 
patients are clinically and 
metabolically stable.
Hypophysitis
2-4
Toxicity resolves to 
Grade 0-1. Therapy with 
pembrolizumab can be 
continued while 
endocrine replacement 
therapy is instituted
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
Hyperthyroidism 
3
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
Hypothyroidism
Therapy with 
pembrolizumab can be 
continued while thyroid 
replacement therapy is 
instituted
Therapy with pembrolizumab can be 
continued while thyroid replacement 
therapy is instituted.
Infusion Reaction
3-4
Permanently discontinue
Permanently discontinue
&(
Infusion R
nfusion R
&(/*(1(35235,(7$5<,1)250$7,21
t per 
per 
$7
e
0$
esolve withi
esolve withi
e.
50
tly discontin
y disco
)2
a 
nce
ce
Resume pem
Resum
patients a
patients 
metab
metab
,1
$5
ves to
ves to
Therapy wi
Therapy w
izumab can 
izumab can
nued while
ued while
docrine repl
ocrine rep
therapy is in
therapy is
7$
3
To
2
1
5
1(
(1
roidism
ism
(1
(1
(1
&(
&

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events (Continued)
Toxicity
Hold 
Treatment 
For Grade
Timing for Restarting 
Treatment
Treatment Discontinuation
Pneumonitis
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per
day within 12 weeks.
3-4
Permanently discontinue
Permanently discontinue
Renal Failure or 
Nephritis
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
3-4
Permanently discontinue
Permanently discontinue
All Other Drug-
Related Toxicity2
3 or Severe
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
Note: Permanently discontinue for any severe or Grade 3 (Grade 2 for pneumonitis) drug-related AE that recurs or 
any life-threatening event.
1 For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by 
greater than or equal to 50% relative to baseline and lasts for at least 1 week then patients should be discontinued.
2 Patients with intolerable or persistent Grade 2 drug-related AE may hold IP at physician discretion.  Permanently 
discontinue IP for persistent Grade 2 adverse reactions for which treatment with IP has been held, that do not 
recover to Grade 0-1 within 12 weeks of the last dose.
After the first cycle, each drug may be given independently on a cyclical regimen according to 
the protocol-defined dose interruptions/delays for CC-486/placebo or pembrolizumab as defined 
in Section 8.2.1 above. Dosing interruptions are permitted in the case of medical / surgical events 
or logistical reasons not related to study therapy (eg, elective surgery, unrelated medical events, 
patient vacation, and/or holidays). Subjects should be placed back on study therapy within 3 
weeks of the scheduled interruption, unless otherwise discussed with the Sponsor. The reason for 
interruption should be documented in the patient's study record.
8.2.2.
Overdose
Overdose, as defined for this protocol, refers to blinded CC-486 and/or pembrolizumab. 
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 mg 
or greater (5 times the dose). No specific information is available on the treatment of overdose of 
pembrolizumab. In the event of overdose, the subject should be observed closely for signs of 
toxicity.  Appropriate supportive treatment should be provided if clinically indicated.
&(/*
ti
/*(1(35235,(7$5<,1)250$7,21
t per
per
$7
e
0$
resolve with
resolve with
se or inabili
or inabil
osteroid to 1
osteroid to 
dnisone or e
nisone
hin 12 week
hin 12 week
50
ma
manently d
ntly d
,1
Toxicity d
Toxicity
weeks o
weeks
redu
red
lele
<
$5
y discontinu
y discontin
(7
5,(
ade 3
de 3 (Grade 
(Grade 
treatment wit
eatment w
seline and la
seline and 
Grade 2 drug
rade 2 dru
 adverse reac
adverse reac
eeks of the la
eks of the la
drug may 
drug m
ose interrup
ose interrup
ve.e Dosing
Dosing
ons not rela
ons not re
on, and/or h
n, and/or 
he schedule
e schedule
on shoul
should
.2.2.
O
Overdose
Overdose
p

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
For CC-486, on a per dose basis, an overdose is defined as any amount over the protocol-
specified dose of blinded CC-486 assigned to a given subject, regardless of any associated 
adverse events or sequelae. On a schedule or frequency basis, an overdose is defined as anything 
more frequent than the protocol required schedule or frequency.
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the case report form. See Section 
11.1 for the reporting of adverse events associated with overdose.
8.3.
Method of Treatment Assignment
Subjects who enter screening will be assigned the next available subject number. All eligible 
subjects will be randomized by IRT to receive CC-486 plus pembrolizumab or placebo plus 
pembrolizumab. Treatment assignment will be performed centrally.
All IP will be managed by the IRT system as a central subject number assignment and 
accountability tool only.
8.4.
Packaging and Labeling
The labels for IPs may include, but are not limited to, sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expiry date (where applicable), medication identification/kit 
number, dosing instructions, storage conditions, and required caution statements and/or 
regulatory statements as applicable. Additional information may be included on the label as 
applicable per local regulations.
8.5.
Investigational Product Accountability and Disposal 
Celgene (or designee) will review with the Investigator and relevant site personnel the process 
for Investigational Product return, disposal, and/or destruction including responsibilities for the 
site versus the responsibilities of Celgene (or designee).
8.6.
Investigational Product Compliance
Accurate recording of all IPs administered will be made in the appropriate section of the 
subject’s case report form (CRF) and source documents. The Investigator or designee is 
accountable for the compliance of all study-specific IPs either administered or in their custody 
during the course of the study.
&(/*(1(35235,(7$5<,1)250$7,21
gible
gible
bo plus
bo plus
ment and 
ment and
me, addres
e, addre
ngth (where
gth (whe
), medicat
medica i
uired caut
uired cau i
mati
ation may
n may
ccountabi
countabi
he Invest
he Investig
sposal, and/
sposal, a
Celgene (or
Celgene (or
al Produc
al Produc
l IP
I s admin
adm
form (
form (CRF
CR
e complian
 complian
se of the stu
se of the st

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
9.1.1.
CC-486 (oral azacitidine)
In general, the use of any concomitant medication/therapies deemed necessary for the care of the 
subject is permitted.
All concomitant treatments, including blood and blood products, must be reported on the CRF. 
Subjects may be administered supportive and palliative care (eg, pain control, anti-nausea, anti-
diarrheal) as clinically indicated throughout the study. 
Myeloid growth factors (granulocyte colony stimulating factor [G-CSF] and granulocyte 
macrophage colony-stimulating factor [GM-CSF]) should be administered according to 
American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology 
(ESMO) guidelines only for the treatment of neutropenic infections.
Antiemetic administration is encouraged during the study, and is required for subjects enrolled in 
the PK population; at the Investigator’s discretion, subjects not enrolled in the PK population
may receive prophylactic antiemetic therapy (eg, a serotonin [5-HT3] receptor antagonist such as  
ondansetron) approximately 30 minutes prior to each dose of CC-486.  
Treatment with antidiarrheal medications should be prescribed at the first sign of diarrhea.  Pre-
medication with antidiarrheal medication for subsequent doses of CC-486 may be appropriate at 
the Investigator’s discretion.
9.1.2.
Pembrolizumab Supportive Care
Subjects should receive appropriate supportive care measures as deemed necessary by the 
treating Investigator.  Suggested supportive care measures for the management of adverse events 
with potential immunologic etiology are outlined below. Where appropriate, these guidelines 
include the use of oral or intravenous treatment with corticosteroids as well as additional anti-
inflammatory agents if symptoms do not improve with administration of corticosteroids.  Note 
that several courses of steroid tapering may be necessary as symptoms may worsen when the 
steroid dose is decreased. For each disorder, attempts should be made to rule out other causes 
such as metastatic disease or bacterial or viral infection, which might require additional 
supportive care. The treatment guidelines are intended to be applied when the Investigator 
determines the events to be related to pembrolizumab. 
Note: if after the evaluation the event is determined not to be related, the Investigator does 
not need to follow the treatment guidance (as outlined below). Refer to Table 6 for dose 
modification guidelines for pembrolizumab. 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. 
&(/*(1(35235,(7$5<,1)250$7,21
CRF.
CRF.
usea, ant
sea, anti-i-
ranulocyte
anulocyte
according t
according 
or Medi
r Med cal
required
quired fo
fo
t enrolled in
enrolle
n [5
[5-HT3] r
HT3] r
se of CC
e of CC-48
prescribed a
prescribe
equent dos
equent do
Care
Care
upportive c
upportiv
upportive c
upportive c
lology
gy are ou
are ou
y
avenous
avenou tr
mptom
mptoms do
d
steroid tap
steroid tap
eased. For e
sed. For 
c disease o
c disease o
re. The trea
. The tre
the events 
the events
te: if after t
e: if after t
not need to
not need to
mo
modifica
dific
t m
t may b
ay 
t

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
9.1.2.1.
Management of pneumonitis
These guidelines may also be used for cases of pneumonitis that may not be related to 
pembrolizumab.
!
For Grade 2 events, treat with systemic corticosteroids. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.
!
For Grade 3-4 events, immediately treat with intravenous steroids.  Administer 
additional anti-inflammatory measures, as needed.
!
Add prophylactic antibiotics for opportunistic infections in the case of prolonged 
steroid administration
9.1.2.2.
Management of Diarrhea/Colitis
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, 
abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such 
as peritoneal signs and ileus).  
!
All subjects who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be substituted via IV infusion.  For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis.
!
For Grade 2 diarrhea/colitis, administer oral corticosteroids. 
!
For Grade 3 or 4 diarrhea/colitis, treat with intravenous steroids followed by high 
dose oral steroids.  
!
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
9.1.2.3.
Management of type 1 diabetes mellitus (if new onset, including diabetic 
ketoacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic acidosis (DKA)
!
For type 1 diabetes mellitus (T1DM) or Grade 3-4 Hyperglycemia
o
Insulin replacement therapy is recommended for type 1 diabetes mellitus and 
for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria.
o
Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and C-peptide.
9.1.2.4.
Management of hypophysitis
!
For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered.
!
For Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by oral 
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be 
&(/*(1(35235,(7$5<,1)250$7,21
nged 
ed 
lit
litis (such 
is (such 
owel perfo
wel pe
advised to
dvised to
ake is not f
ake is no
n.  For Gra
.  For Gra
nfirm
nfirm or ru
or
m
oral cortico
oral cortic
at wi
t with
th
i
i
h ntn r
Grade 1 or 
Grade 1 
n 4 weeks.
4 wee
e 1 diabete
e 1 diabete
A]) or
A]) or ≥ G
≥G
metabolic
metabolic
didiabetes m
abetes m
Insulin rep
Insulin rep
fo
for Gra
r G
o
Eva
Ev
.2.4.
2.4.
M
!

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
started and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.
9.1.2.5.
Management of hyperthyroidism or hypothyroidism
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated based 
on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
!
Grade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism):
o
In hyperthyroidism, non-selective beta-blockers (eg, propranolol) are 
suggested as initial therapy.
o
In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine 
or liothyroinine, is indicated per standard of care.
!
Grade 3-4 hyperthyroidism 
o
Treat with an initial dose of IV corticosteroid followed by oral corticosteroids. 
When symptoms improve to Grade 1 or less, steroid taper should be started 
and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.
9.1.2.6.
Management of hepatic abnormalities
!
For Grade 2 events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).
o
Treat with IV or oral corticosteroids
!
For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours. 
When symptoms improve to Grade 1 or less, a steroid taper should be started and continued over 
no less than 4 weeks.
9.1.2.7.
Management of renal failure or nephritis
!
For Grade 2 events, treat with corticosteroids.
!
For Grade 3-4 events, treat with systemic corticosteroids.
!
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
9.1.2.8.
Management of infusion reactions
Table 7 shows treatment guidelines for subjects who experience an infusion reaction associated 
with the administration of pembrolizumab.
&(/*(1(35235,(7$5<,1)250$7,21
levothy
levothyrox
rox
y
ed by
ed by oral
ora
y
l
oid taper sh
d taper sh
acement of
ement of
se is tapere
se is tap
n tests more
n tests m
osteroi
osteroids
ds
th intraven
th intraven
or less, a s
or less,
renal failu
renal failu
events, trea
vents, tr
e 3-4 event
4 even
n symptom
n symptom
ntinued ov
tinued ov
Manag
Manag
lele 7 shows
shows
wi
with
th
i
the adm
the adm
h

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 7:
Infusion Reactions
NCI CTCAE Grade
Treatment
Premedication at
Subsequent Dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated
Increase monitoring of vital signs 
as medically indicated until the 
subject is deemed medically 
stable in the opinion of the 
Investigator.
None
Grade 2
Requires infusion interruption 
but responds promptly to 
symptomatic treatment (eg, 
antihistamines, NSAIDS, 
narcotics, IV fluids); 
prophylactic medications 
indicated for ≤ 24 hrs
Stop Infusion and monitor 
symptoms.
Additional appropriate medical 
therapy may include but is not 
limited to:
•
IV fluids
•
Antihistamines
•
NSAIDS
•
Acetaminophen
•
Narcotics
Increase monitoring of vital signs 
as medically indicated until the 
subject is deemed medically 
stable in the opinion of the 
Investigator.
If symptoms resolve within one 
hour of stopping drug infusion, 
the infusion may be restarted at 
50% of the original infusion rate 
(eg, from 100 mL/hr to 50 
mL/hr).  Otherwise dosing will 
be held until symptoms resolve 
and the subject should be 
premedicated for the next 
scheduled dose.
Subjects who develop Grade 2 
toxicity despite adequate 
premedication should be 
permanently discontinued 
from further trial treatment 
administration.
Subject may be premedicated 1.5 
hrs. (± 30 minutes) prior to 
infusion of pembrolizumab with:
Diphenhydramine 50 mg p.o. (or 
equivalent dose of 
antihistamine).
Acetaminophen 500-1000 mg 
p.o. (or equivalent dose of 
antipyretic).
&(/*(1(3
(/
35235,(7$5<
signs 
igns 
il the
l the
cally
cally
of the
of the
reso
esolve with
lve with
pping drug i
pping drug
sion may be
sion may be
of the origin
of the origin
g, from 100 
from 100
mL/hr).  Ot
mL/hr).  O
be
be held u
held
and th
nd 
pre
5<,1)250$7,21
$7
ated 1.5
ated 1.5
or to
zumab with
zumab with
e 50 mg p.o
50 mg p.
se of 
e of 
ne).
ne).
minophen 50
inophen 50
(or equivale
or equival
ntipyretic).
pyretic).
$7
$7
35
5<
$7

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 7:
Infusion Reactions (Continued)
NCI CTCAE Grade
Treatment
Premedication at
Subsequent Dosing
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial improvement; 
hospitalization indicated for 
other clinical sequelae (eg, renal 
impairment, pulmonary 
infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support indicated
Stop Infusion.
Additional appropriate medical 
therapy may include but is not 
limited to:
•
IV fluids
•
Antihistamines
•
NSAIDS
•
Acetaminophen
•
Narcotics
•
Oxygen
•
Pressors
•
Corticosteroids
•
Epinephrine
Increase monitoring of vital signs 
as medically indicated until the 
subject is deemed medically 
stable in the opinion of the 
Investigator.
Hospitalization may be indicated. 
Subject is permanently 
discontinued from further trial 
treatment administration.
No subsequent dosing
Appropriate resuscitation equipment should be available in the room and a physician readily available 
during the period of drug administration.
CTCAE = Common Terminology Criteria for Adverse Events;  hr = hour; IV = intravenous(ly); NCI = National 
Cancer Institute; NSAID = non-steroidal anti-inflammatory drug;  p.o. = oral(ly)
Appropriate resuscitation equipment should be available in the room and a physician readily available during the 
period of drug administration.
For Further information, please refer to CTCAE v4.0 at http://ctep.cancer.gov
9.2.
Prohibited Concomitant Medications and Procedures
The following concomitant medications are prohibited during the course of the study:
!
Cytotoxic, chemotherapeutic, targeted, hormonal, or investigational agents/therapies 
or any other anticancer treatment.
!
Vidaza (azacitidine injection), decitabine, or other demethylating agents.
!
Other PD-1 or PD-L1 inhibitors
!
Radiation therapy
o
Note:  Radiation therapy to a symptomatic solitary lesion or to the brain may 
be considered on an exceptional case by case basis after consultation with 
&(/*(1(35235,(7$5<,1)250$7,21
y
he
ay be indica
ay be indica
manently 
manently 
d from
d from furt
furt
m
t administr
administr
5<
$7
uld be availa
ld be availa
n.
35
52
eria for Adve
eria for Adve
roidal anti
roidal anti-i
ment should b
ent should 
n.n.
ease refer to 
ease refer to 
ibited Co
ibited Co
ng concomit
ng concomi
Cy
Cytotox
oto
y
or an
r a
!
V

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Sponsor.  The subject must have clear measurable disease outside the radiated 
field.  Administration of palliative radiation therapy will be considered 
clinical progression for the purposes of determining PFS.
!
Live vaccines within 30 days prior to the first dose of trial treatment and while 
participating in the trial.  Examples of live vaccines include, but are not limited to, the 
following: measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 
flu, rabies, bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza 
vaccines for injection are generally killed virus vaccines and are allowed. However, 
intranasal influenza vaccines (eg, Flu - Mist®) are live attenuated vaccines, and are 
not allowed.
!
Glucocorticoids for any purpose other than to modulate symptoms from an event of 
clinical interest (ECI), use as a pre-medication for chemotherapeutic agents specified 
in the protocol, or for use as a pre-medication in subjects with a known history of an 
IV contrast allergy administered as part of CT radiography. Replacement doses of 
steroids (for example, prednisone 5-7.5 mg daily) are permitted while on study. 
Subjects who, in the assessment by the Investigator, require the use of corticosteroids 
for any other clinical management should be discussed with medical monitor.
9.3.
Required Concomitant Medications and Procedures
Not applicable.
&(/*(1(35235,(7$5<,1)250$7,21
,
are
an event of 
an event of 
gents speci
ents spec
own history
wn histo
acement do
acement d
d while on
whil
e the use o
the use o
with medic
with med
Procedu
Proced

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
10.
STATISTICAL ANALYSES
10.1.
Overview
This is a placebo-controlled, double-blind, randomized, phase 2 trial designed to estimate the 
efficacy and safety/tolerability of CC-486 plus pembrolizumab and placebo plus pembrolizumab, 
in subjects with previously treated metastatic non-small cell lung cancer. The primary endpoint is 
PFS based on Investigator review. 
The sections below lay out the proposed statistical considerations and analyses. The detail
statistical analysis methods will be documented in the statistical analysis plan (SAP).
10.2.
Study Population Definitions
10.2.1.
Intent-To-Treat Population
The intent-to-treat (ITT) population will consist of all randomized subjects.  All efficacy 
analyses will be based on the ITT population, unless otherwise specified.  The efficacy analyses 
will be performed according to treatment assigned at randomization.
10.2.2.
Safety Population
The safety population will consist of any enrolled subjects who received at least 1 dose of IP.  
All safety analyses will be based on the Safety population, unless otherwise specified.  The 
treatment groups for the safety analyses are based on the treatment as received if different from 
the pre-planned randomization.
10.2.3.
PK Population
The PK analysis population will include all randomized subjects who have evaluable 
concentration data to determine the pharmacokinetic parameters from at least 1 dose of CC-486.
10.2.4.
Biomarker Population
The biomarker analysis population will include all randomized subjects who received at least 1
dose of IP, provided consent for exploratory biomarker studies, and had at least 1 predose 
biomarker tissue collected and deemed of adequate quality for biomarker analysis. 
10.3.
Sample Size and Power Considerations
The primary goal of this study is to provide estimates of the difference in efficacy and safety 
between CC-486 plus pembrolizumab and placebo plus pembrolizumab. 
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab. Primary analysis will be conducted when 70 PFS events occur.
Selected hypothetical scenarios are presented in Table 8 with confidence interval and power 
estimates, when approximately 70 PFS events have occurred.
The table below demonstrates the hypothetical power of testing the null hypothesis H0: λT/ λC=1, 
against the two sided alternative H0: λT/ λC≠1,assuming that time to PFS events in both treatment 
&(/*(1(35235,(7$5<,1)250$7,21
s s 
ects.  All ef
ects.  All 
ified.  The 
ed.  The 
on.n.
cts who rec
cts who re
atatioion, unl
n, un e
on the trea
on the tre
de all ran
de all r
d
e pharmaco
e pharmaco
lation
lation
populat
populatioi n w
onsent for 
onsent for 
ollected and
ollected and
ample Siz
ample Siz
mary goal
goal
y
of
of
l
en CC
en C -486
486
pproximate
pproximate
plplacebo p
acebo p
lect

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
arms follow exponential distributions, and λC is the monthly hazard rate of the survival 
distribution in the control arm, and  λT is the monthly hazard rate of the survival distribution in 
the experimental arm (CC-486+pembrolizumab).
Table 8:
Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio
Combo Treatment Median PFS (month) 
5.5
5.0
4.6
Total PFS events
74
75
76
Power (%) w/two-sided α=0.10
1
82.4
71.7
59.4
HR with [two-sided 90% CI] 
0.55 [0.38,0.81]
0.60 [0.41,0.88]
0.65 [0.45,0.95]
1 These calculations assume the median PFS in pembrolizumab alone is 3.0 months (Garon, 2014). And lost to 
follow-up (to assess PFS events) rate is 10% at the end of study. 
The power calculations are conducted with East 5.4. 
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics, while gender, race and other categorical variables will be provided using frequency 
tabulations.  Medical history data will be summarized using frequency tabulations by system 
organ class and preferred term.
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both treatment 
and follow-up phases.  A summary of subjects enrolled by site will be provided. Protocol 
deviations will be summarized using frequency tabulations.
10.6.
Efficacy Analysis
10.6.1.
Primary Efficacy Endpoint
The primary endpoint PFS will be defined as the time from the randomization date to disease 
progression assessed by Investigator according to RECIST version 1.1 guideline or death due to 
any cause, whichever occurs first.  
Subjects who are alive and progression-free at the cut-off date of the PFS analyses will be 
censored at the date of the last tumor evaluation.  If subjects  begin new anti-cancer therapy prior 
to documented progression, PFS will be censored at the last assessment prior to receiving the 
anti-cancer therapy. Subjects with 2 or more missing response assessments prior to a visit with 
documented disease progression (or death) will be censored at the last visit where the subject 
was documented to be PFS event-free.  A sensitivity analysis will be performed with censoring 
rules that follow the principles of assigning the date of event based on the time of the first 
evidence of objective progression or death regardless of violations, discontinuation of IP or 
change of therapy. 
PFS will be summarized by median progression-free survival time (including two-sided 90% 
confidence interval [CI]) for each treatment group and within each strata.  The hazard ratio and a 
&(/*
m
(/*(1(35235,(7$5<,1)250$7,21
7
$7
45,0.95]
,0.95]
$7
$7
0$7
d lost to
lost to
mmarized us
marized u
e provided 
provided
quency
quenc tabu
y
, entered, d
, entered, d
using frequ
using fre
ts enrolled 
ts enrolled
uency tabul
uency tabu
Endpoint
Endpoint
will be de
will be de
y Invest
nv
igat
iga
r occurs fir
occurs fi
e alive and 
e alive and
e date of th
date of t
nted progre
ted progre
ncer therapy
ncer therap
ented di
ented di
as docume
as docume
rulu es that 
that 
viden
viden

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
two-sided 90% CI will be estimated by using Cox proportional hazard model with treatment, and 
any stratification factors as model covariates.  The Kaplan-Meier curve for PFS will be presented
for each treatment group and strata.
10.6.2.
Secondary Endpoints
10.6.2.1.
Overall Survival
Overall survival (OS) will be defined as the time from the date of randomization to the date of 
death (any cause).  Subjects who are alive will be censored at the last time that the subject was 
known to be alive. The OS analysis may also be conducted at the time when 70 deaths occur, in 
addition to when the primary analysis is performed.
Medians of overall survival including two-sided 90% CI for each treatment group will be 
calculated.  The hazard ratio and a two-sided 90% CI will be estimated using Cox proportional 
hazard model with treatment, and all stratification factors in the model.  The Kaplan-Meier curve 
for survival will be presented for each strata and treatment group.
10.6.2.2.
Overall Response Rate (ORR)
Overall response rate is the percentage of subjects that achieve a confirmed complete or partial 
response as assessed by the Investigator using RECIST version 1.1 guideline. This rate will be 
presented for each treatment group and strata.  The 90% CI of the response rates will be 
provided.  A two-sided 90% CI of the Response rate differences between pembrolizumab plus 
placebo and pembrolizumab plus CC-486 arm, with each strata and overall will be provided.
10.6.2.3.
Disease Control Rate (DCR)
The percentage of disease control (i.e., confirmed SD, CR or PR) according to RECIST 1.1 will 
be analyzed in the same manner as ORR.  When SD is believed to be best response, it must meet 
the minimum duration of 18 weeks from randomization.
10.6.2.4.
irPFS, irORR and irDCR per irRECIST
Exploratory endpoints such as irPFS, irORR, and irDCR assessed by Investigator according to 
irRECIST will be analyzed using statistical methods described previously for similar primary or 
secondary endpoints.
10.6.3.
Subgroup Analysis
The effect of treatment on the efficacy variable OS, PFS, and DCR may be investigated within 
subgroups defined by selected baseline prognostic variables and any stratification factors.
The methods described in previous statistical analysis sections will be used for each subgroup 
separately. A forest plot may also be provided.
10.7.
Safety Analysis
Safety analysis will be performed using the safety population. Safety and tolerability will be 
monitored through continuous reporting of all AEs and SAEs, laboratory abnormalities, and 
incidence of subjects experiencing adverse events resulting in dose reductions, dose 
&(/*(1(35235,(7$5<,1)250$7,21
as
cur, in
ur, in
will
will be
be
ox proportio
ox proporti
Kaplan
Kapl
-Me
Me
confirmed
confirmed
on 1.1 guide
n 1.1 gui
of
of the
the
f
resp
re
fferences be
ferences b
ach strata 
ach stra
firirmed 
med SD,
SD,
.  When SD
.  When 
om 
m rando
rand m
rDCR per
DCR per
as 
as irirPFS, 
PFS, ir
ed using sta
ed using
roup Anal
roup Ana
f treatment 
f treatment
s defined b
defined b
methods des
ethods d
parately
arately. A
. A
10.7.
0.7.

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
interruptions, and/or premature discontinuation of study drugs. TEAEs, TEAEs leading to death 
or discontinuation from treatment, events assessed as Grade 3 or Grade 4, events of clinical 
interest, vital signs, weight, clinical laboratory information, and concomitant 
medications/procedures will be tabulated and summarized.
Treatment-emergent adverse events will be coded according to MedDRA. All TEAEs will be 
summarized by MedDRA system organ class and preferred term, frequency, severity grade based 
on the CTCAE (Version 4.0) and relationship to treatment. Serious adverse events, events of 
clinical interest, and events leading to discontinuation or death will be listed separately.
10.8.
Pharmacokinetic Analysis
When appropriate, plasma PK samples collected will be analyzed for CC-486 concentration 
determination using a validated high-performance liquid chromatography/tandem mass 
spectrometric method.
10.8.1.
Plasma Concentrations
By-subject listing of pharmacokinetic blood sample collection times as well as derived sampling 
time deviations will be provided.  CC-486 plasma concentrations will be summarized using 
descriptive statistics (N, arithmetic mean, standard deviation, standard error, minimum, median, 
maximum, percent coefficient of variation, geometric mean, and geometric percent coefficient of 
variation) for each cycle, if/when appropriate.  Concentrations that are below the limit of 
quantitation (BLQ) will be treated as zero for the computation of descriptive statistics. Missing 
concentrations and concentrations from blood samples collected more than ± 10% of nominal 
time will be omitted from the calculation of descriptive statistics.
Individual subject concentration-time data and mean concentration-time data for each cycle will 
be graphically presented on linear and semi-logarithmic scales.
Following single dose administration, predose samples that are BLQ or missing will be assigned 
a numerical value of zero for the calculation of AUC.  Any anomalous concentration values 
observed at predose will be identified in the clinical study report (CSR) and used for the 
computation of AUC.  Pharmacokinetic parameters will be computed if the anomalous value is 
not greater than 5% of the Cmax.  If the anomalous value is greater than 5% of Cmax, the computed 
pharmacokinetic parameters for the given subject will be dropped from the pharmacokinetic 
analysis.  
Any other BLQ concentrations will be assigned a value of zero if they precede quantifiable 
samples in the initial portion of the profile.  A BLQ value that occurs between quantifiable data 
points, especially prior to Cmax, will be evaluated to determine if an assigned concentration of 
zero makes sense, or if reanalysis or exclusion of the data is warranted.  Following Cmax, BLQ 
values embedded between 2 quantifiable data points will be treated as missing when calculating 
AUC.  BLQ values occurring at the end of the collection interval (after the last quantifiable 
concentration) will be treated as missing data.  If consecutive BLQ concentrations are followed 
by quantifiable concentrations in the terminal portion of the concentration curve, these quantified 
values will be excluded from the pharmacokinetic analysis by assigning them a value of missing, 
unless otherwise warranted by the concentration-time profile.  For the purpose of analysis, these 
trailing BLQ values may be designated as zero in the dataset if the pharmacokinetic program 
&(/*(1(35235,(7$5<,1)250$7,21
tration
tration
mass
ass
as well as d
s well as d
will be sum
will be sum
andar
andard erro
and geome
and geom
tions that a
tions that a
putati
putation of
on of
les collecte
les collec
riptive stati
iptive stat
d mean co
d mean co
mi
mi-lologari
garithm
thm
i
predose sa
predos
lculat
cu
ioion o
n o
ntified in th
ntified in th
acokinetic
acokinetic
Cma
max.  If
.  
thth
f
meters for th
meters for t
concentrat
concentrat
e init
e initial po
ial po
pecially pri
cially pri
akes sense, 
kes sense,
es embedde
es embedd
AUC.  BLQ 
AUC.  BLQ
concentra
oncentra
y qua
y qua

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
used to do the analysis (such as WinNonlin®) will treat trailing zero values as missing when 
calculating AUC.
Actual sampling times will be used in the calculations of pharmacokinetic parameters that will be 
derived using noncompartmental methods with Phoenix™ WinNonlin® Professional Version 6.3, 
or higher, 
  Graphics may be prepared 
with SAS Version 9.1, or higher; or Excel 2007, or higher; Phoenix™ WinNonlin® Professional 
6.3, or higher; or S-Plus 8.2., or higher 
.
10.8.2.
Pharmacokinetic Parameters
The following PK parameters will be calculated for CC-486:
AUCinf
Area under the plasma concentration-time curve from Time 0 extrapolated 
to infinity, calculated as [AUCt + Ct/∀z].  Ct is the last quantifiable 
concentration. No AUC extrapolation will be performed with unreliable 
∀z.  If AUC %Extrap is ≥25%, AUCinf will not be reported
AUCt
Area under the plasma concentration-time curve from Time 0 to the time 
of the last quantifiable concentration, calculated by linear trapezoidal 
method when concentrations are increasing and the logarithmic 
trapezoidal method when concentrations are decreasing.
Cmax
Maximum observed plasma concentration, obtained directly from the 
observed concentration versus time data.
Tmax
Time to Cmax, obtained directly from the observed concentration versus 
time data.
t1/2
Terminal phase half-life in plasma, calculated as [(ln 2)/ ∀z].  t1/2 will only 
be calculated when a reliable estimate for ∀z can be obtained.  
CL/F
Apparent total clearance, calculated as [Dose/AUCinf]. 
Vz/F
Apparent volume of distribution, calculated as [(CL/F)/∀z ].
The following PK parameters for CC-486 will be calculated for diagnostic purposes and listed, 
but they will not be summarized:
∀z
Apparent terminal rate constant, calculated by linear regression of the 
terminal portion of the log-concentration versus time curve in plasma.  
Visual assessment will be used to identify the terminal linear phase of the 
concentration versus time profile.  A minimum of three data points will be 
used for calculation.  
∀z will not be estimated if the terminal phase of the log-concentration 
versus time profile does not exhibit a linear decline phase, or if the 
regression coefficient < 0.8.  
&(/*(1(35235,(7$5<,1)250$7,21
0 e
0 extxtrapol
rapol
uantifiable
antifiable
ed with unr
ed with unr
eported
eported
ve from
e from Ti
Ti
m
ulated by lin
ated by lin
sing and the
ing and
ons are dec
ons are dec
nc
ncentrati
entration
on
us t
s time data
ime da
directly fro
directly fro
e half
e half-f life i
li
d when a r
when a r
rent total cl
ent total cl
Apparent v
Apparent v
K parameter
parameter
ot be summ
t be sum

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
∀z lower
Lower limit of time (h) included in the calculation of ∀z. 
∀z N
Number of data points used in the calculation of ∀z.
∀z upper
Upper limit of time (h) included in the calculation of ∀z.
Rsq
Regression coefficient for calculation of ∀z.  
AUC % Extrap
Percentage of AUCinf due to extrapolation from the last quantifiable time 
point to infinity.
10.8.3.
PK Analyses
By-subject listing of pharmacokinetic parameters will be provided.  The pharmacokinetic 
parameters will also be summarized using descriptive statistics (N, arithmetic mean, standard 
deviation, standard error, minimum, median, maximum, percent coefficient of variation, 
geometric mean, and geometric percent coefficient of variation) for each cycle.  Also, when 
appropriate, graphical representations (i.e., scatter plots, box plots, etc) may be used to visualize
the results.
The effect of pembrolizumab on the PK of CC-486 will be assessed using graphic comparison 
and descriptive stats.
Exploratory analysis may be conducted to investigate the relationship between PK parameters 
and efficacy endpoints.
10.9.
Interim Analysis
No interim analysis of efficacy is planned for this study.
10.10.
Other Topics
10.10.1.
Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will be established and will include 
medical oncologists and a statistician, all of whom are not otherwise involved in the study 
conduct.  During the course of the study, the DMC will review the safety data regularly. The first 
DMC meeting will occur when 10 subjects in each arm have safety data from at least one cycle 
of treatment, with subsequent meetings approximately every 6 months or more often if requested 
by the DMC Chairman. The DMC will offer recommendations to continue, modify or stop the 
study based only on periodic evaluations of comparative safety data, in accordance with criteria 
outlined in the DMC Charter. An independent statistician will prepare the reports to the DMC 
members for each scheduled meeting. Operational details for the DMC will be detailed in the 
DMC charter.
10.10.2.
Steering Committee
The conduct of this trial will be overseen by a Steering Committee (SC), presided over by the 
coordinating principal Investigator and if possible the representative regional Investigators from 
&(/*(1(35235,(7$5<,1)250$7,21
me
acokinetic
acokineti
c m
c mean, sta
ean, s
nt of variat
nt of variat
ch cycle.  A
h cycle.  
etc) may be
etc) may be
ssessed usi
sessed us
the relat
the relatioi
d for this s
d for this
Committe
Committe
onitoring Co
nitoring
nd a stati
d a st
sti
he course of
e course of
will
will occur w
occur w
l
wi
with
th
i
subse
subse
h
MC Chairma
C Chairma
ased only o
ased only o
ned in the D
ned in the 
embers for
embers for
DMC cha
DMC cha

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
countries participating in this study.  The SC will serve in an advisory capacity to the Sponsor.  
Operational details for the SC will be detailed in a separate SC charter.
Note: The SC is separate from the DMC.
&(/*(1(35235,(7$5<,1)250$7,21

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study. It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria in Section 11.3), regardless of etiology. Any 
worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-
existing condition) should be considered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the CRF rather than the individual signs or symptoms of the diagnosis or 
syndrome. 
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be 
reported on the overdose CRF. (See Section 8.2.2 for the definition of overdose.) Any sequela 
of an accidental or intentional overdose of an investigational product should be reported as an 
AE on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported 
on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be 
identified as the cause of the event on the SAE report form and CRF but should not be reported 
as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for CC-486 and 
pembrolizumab overdose. Actual treatment should depend on the severity of the clinical situation 
and the judgment and experience of the treating physician.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by the Investigator from the time the subject signs informed consent 
until 30 days after the last dose of either study drug and those SAEs made known to the 
Investigator at any time thereafter that are suspected of being related to IP. Adverse events and 
SAEs will be recorded on the AE page of the CRF and in the subject’s source documents.  All 
SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigator’s knowledge 
of the event by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.
In addition, events known as pembrolizumab Events of Clinical Interest (ECI) must also be 
recorded on the Adverse Event CRFs or Overdose CRF, depending on the event, and reported 
within 24 hours of the Investigator’s knowledge of the event, regardless of whether or not the 
Investigator considers the event related to the IP. If the event meets serious criteria (SAE), the 
event must also be reported to Celgene Drug Safety also within 24 hours by facsimile, or other 
appropriate method, using the SAE Report Form, or approved equivalent form as outlined in 
Section 11.5. 
&(/*(1(35235,(7$5<,1)250$7,21
y
pre
pre-
corded on
rded o
s or 
s or 
be reporte
be reporte
h an AE sh
h an AE sh
overdose.)
erdose
should be 
should be
n the sequel
the seque
lting 
ing in the
and CRF bu
nd CRF bu
ored as app
ored as app
wn specific
wn specifi
uld depend
uld depen
ing physici
ing physici
during the s
during the
ters:  the su
ters:  the
cal findings
findings
l
y the Invest
the Inve
y
st dose of e
t dose o
me thereafte
me therea
ded on the
ded on the
eported to 
eported to 
by
by f
y acsimil
acsimil
f
t form.
form.
dititioion,n, even
even
orded on th
rded on t
wi
within
thin
i
24 h
24 h
nvest
nvestigi

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
See Section 11.7 for detailed guidance on the reporting of pembrolizumab ECIs.  
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to: 
11.2.1.
Seriousness 
A serious adverse event (SAE) is any AE occurring at any dose that:
!
Results in death;
!
Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);
!
Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);
!
Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);
!
Is a congenital anomaly/birth defect;
!
Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:
!
A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE. 
!
Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.
!
The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.
!
A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.
!
Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.
!
A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the CRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.
&(/*(1(35235,(7$5<,1)250$7,21
mediate
ediate
zati
ation
on
ength of st
ngth of s
ant
antial 
ial disru
disru
 that may n
that may 
itity, but ma
y, but ma
ne of the ot
ne of the 
sed in decid
sed in dec
spitalizatio
pitalizatio
rotocol the
rotocol the
ation fo
for a 
r a 
nt or monito
nt or mon
n condit
n condi io
nistration o
nistration
ion.  Howe
n.  Howe
uch transfu
uch trans
A procedu
A procedu
endosc
endosc
hosp
os
r

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
An elective treatment of or an elective procedure for a pre-existing condition 
unrelated to the studied indication, that has not worsened from baseline. 
!
Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
11.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity / intensity of the event. 
The severity / intensity of AEs will be graded based upon the subject’s symptoms according to 
the current active minor version of the Common Terminology Criteria for Adverse Events 
(CTCAE, Version 4.0); http://ctep.cancer.gov/protocolDevelopment/electronic_applications/
ctc.htm#ctc_40
Adverse events that are not defined in the CTCAE should be evaluated for severity / intensity 
according to the following scale:
!
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!
Grade 3 = Severe – marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible
!
Grade 4 = Life threatening – extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice 
care probable
!
Grade 5 = Death - the event results in death
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected:
a causal relationship of the adverse event to IP administration is 
unlikely or remote, or other medications, therapeutic 
interventions, or underlying conditions provide a sufficient 
explanation for the observed event.
Suspected:
there is a reasonable possibility that the administration of IP 
caused the adverse event.  ‘Reasonable possibility’ means there 
is evidence to suggest a causal relationship between the IP and 
the adverse event.
&(/*(1(35235,(7$5<,1)250$7,21
event.
event
oms accord
ms accord
Adverse Ev
dverse Ev
ctronic_app
ronic_
uated for se
ated for s
no limitat
no limitati
limitat
limitatioion
vent
ventioion/the
n/the
atatioion n in ac
n ac
required, h
required, h
g g – extrem
extre
edical inte
edical int
h - th
the eve
e eve
y
must deter
must deter
an AE/SAE
n AE/SA
ot suspected
suspected
S

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Causality should be assessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes 
available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.
11.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
11.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation, interruption, or reduction of IP, as appropriate) and report if concomitant 
and/or additional treatments were given for the event. 
11.2.6.
Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE). 
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!
results in discontinuation from the study;
!
requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
!
is judged to be of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing 
condition.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE. If 
possible, the laboratory abnormality should be recorded as a medical term and not simply as an 
abnormal laboratory result (eg, record thrombocytopenia rather than decreased platelets).
11.4.
Pregnancy
All pregnancies, suspected pregnancies and lactation occurring in either a female subject of 
childbearing potential or partner of a male subject are immediately reportable events.
&(/*(1(35235,(7$5<,1)250$7,21
f the
he
E, as appli
E, as app
port if conc
port if conc
AEs and SA
Es an
e subject’s 
subject’
recovered w
ecovered
s
to be an A
to be an 
om 
m the stud
e stu
ificat
ic ion/ i
n/ i
of significan
f signific
or organ tox
or organ t
verit
erity y grade
grade
umented as
umented 
tory
ory abnorm
abnorm
y
rome shoul
rome shou
of a diagno
of a diagn
ossible, the
ossible, the
abnorm
bnormalal

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
11.4.1.
Females of Childbearing Potential
Pregnancies, suspected pregnancies (including elevated β-hCG or a positive pregnancy test in a 
female of childbearing potential regardless of age or disease state) and lactation of a female 
subject that occur during the trial or within 120 days of completing the trial (or longer if required 
by local requirements), or 30 days following cessation of treatment if the subject initiates new 
anticancer therapy, whichever is earlier, are considered immediately reportable events.  
Investigational product is to be discontinued immediately.  The pregnancy, suspected pregnancy, 
or positive pregnancy test, or lactation must be reported to Celgene Drug Safety immediately by 
facsimile, or other appropriate method, using the Pregnancy Initial Report Form, or approved 
equivalent form.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.
The female subject should be referred to an obstetrician-gynecologist, preferably one 
experienced in reproductive toxicity for further evaluation and counseling.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate 
method, within 24 hours of the Investigator’s knowledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal deaths that occur within 30 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 30 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2.
Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant while the 
subject is receiving investigational product or within 3 months of the last dose of IP, the male 
subject taking IP should notify the Investigator, and the pregnant female partner should be 
advised to call their healthcare provider immediately. The female partner should be referred to an 
obstetrician-gynecologist, preferably one experienced in reproductive toxicity for further 
evaluation and counseling.  Male subjects should avoid fathering a child until 3 months after the 
last dose of IP (or longer if required by local requirements). The ICF will address any country-
specific requirements, as needed.
11.5.
Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF.  Any serious adverse event, or 
follow up to a serious adverse event, including death due to any cause other than progression of 
the cancer under study that occurs to any subject from the time the consent is signed through 90 
days following cessation of treatment, or 30 days following cessation of treatment if the subject 
initiates new anticancer therapy, whichever is earlier, whether or not related to the Sponsor's 
&(/*(1(35235,(7$5<,1)250$7,21
by
ved 
ed 
nd m
nd must
ust
m
her norm
er norma
d equivalen
d equivalen
ferably
ferably on
y
ing.
ng.
ortion
ortion), , th
th
outcome m
outcome m
y y by facsim
by facsi
of the even
e even
rth should b
rth should 
h afte
h after 30
r 30 d
uld also be 
uld also be 
ithin 24 hou
thin 24 hou
pproved eq
proved e
subject taki
subject tak
gatatioional pr
nal pr
d notify
d not
the
th
y
healt
ealthcare p
hcare
co
colologigist, pr
st, pr
counseling
counselin
IP
IP (or long
(or long
requiremen
uiremen
5.5.
Re
Re
Any AE th
Any AE t
ddi
ddititi
i o

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
product  must be reported to Celgene Drug Safety within 24 hours of the Investigator’s 
knowledge of the event by facsimile, or other appropriate method, using the SAE Report Form, 
or approved equivalent form.  This instruction pertains to initial SAE reports as well as any 
follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to study drugs) that occur during 
the study (from the time the subject signs informed consent until 90 days after the last dose of 
either IP) or any SAE made known to the Investigator at anytime thereafter that are suspected of 
being related to IP.  SAEs occurring prior to treatment (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include a concise summary
of hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data should be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the IRB/Ethics 
Committee (EC) of the SAE and providing them with all relevant initial and follow-up 
information about the event. The Investigator must keep copies of all SAE information on file 
including correspondence with Celgene and the IRB/EC.
11.5.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (eg, missing causality assessment) may be handled by phone.
11.6.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to CC-486 based on the Investigator Brochure.
In the United States, all suspected unexpected serious adverse reactions (SUSARs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.
For the purpose of regulatory reporting in the EEA, Celgene Drug Safety will determine the 
expectedness of events suspected of being related to the other IP, pembrolizumab based on the 
Pembrolizumab Investigators Brochure for the product.
Events of  disease progression for the disease under study (including deaths due to disease 
progression for indications that are considered to be fatal) will be assessed as expected adverse 
events and will not be reported as expedited safety reports to regulatory authorities.
&(/*(1(35235,(7$5<,1)250$7,21
of 
of 
ed.d.
summary
summary
s b
s been
een
gene Drug 
ne Drug 
ed in a sub
ed in a su
Safet
Safety.y.
nforming th
orming
ialal and fo
and foll
all SAE in
all SAE in
m Celgene
Celgene
expect
expected to
ed to
essment) m
ssment) 
Adverse E
Adverse E
g, Cel
g, Celgene
g
o CC
CC-486
486 b
ted unexpe
ed unexpe
anner in acc
nner in ac
e European 
e European
eport in an 
port in an
erned, susp
erned, susp
2001/20/E
001/20/
n of adverse
of adverse
se (ENTR/C
(ENTR/
he purpose
e purpos
xpectedness
xpectedness
Pembroliz
Pembroliz
ent

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Celgene or its authorized representative shall notify the Investigator of the following 
information:
!
Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (i.e., SUSAR);
!
Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Sponsor and the IRB/EC.  (See Section 15.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Celgene Drug Safety contact information, please refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pregnancy Report Form Completion Guidelines.
11.7.
Pembrolizumab Events of Clinical Interest
Selected non-serious and serious adverse events are also known as ECIs and must be reported to 
the Sponsor.
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must be 
reported within 24 hours to the Sponsor if it causes the subject to be excluded from the trial, or is 
the result of a protocol-specified intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/randomization through 30 days following 
cessation of treatment, any ECI, or follow up to an ECI, whether or not related to the Sponsor’s 
products, must be reported within 24 hours to the Sponsor, either by entering all ECIs of 
overdose on the Overdose CRF or by entering all other ECIs on the AE CRF within 24 hours of 
the Investigator’s knowledge of the event, regardless of whether or not the Investigator considers 
the event related to the IP. If the event meets serious criteria (SAE), the event must also reported 
to Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
Events of clinical interest for this trial include:
1. an overdose of pembrolizumab, as defined in Section 8.2.2 - Overdose, that is not 
associated with clinical symptoms or abnormal laboratory results. See Section 11.1 for a 
description of how overdoses of pembrolizumab are to be documented (with or without 
associated adverse events).
2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by way of protocol-specified laboratory 
testing or unscheduled laboratory testing.*
&(/*(1(35235,(7$5<,1)250$7,21
n 
Adverse Ev
Adverse Ev
tion Guide
tion Guid
wn 
wn as ECIs
as EC
is signed u
s signed u
an ECI, th
an ECI, th
uses the sub
ses the su
n, including
n, including
ebo treatm
ebo treatm
ment allo
ment all ca
follo
l w up 
w up 
in 24 hours
in 24 hours
RF or by
RF or by en
y
dge of
of the e
the e
f
IP. If the e
IP. If the e
fety y wi
within 
thin
i
m, or approv
m, or approv
ical intere
cal intere
n overdose 
verdose 
associ
associated
ated
descrip
descrip
asso
asso
2.2.

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
* Note:  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional evaluation for an underlying etiology.
&(/*(1(35235,(7$5<,1)250$7,21

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
12.
DISCONTINUATIONS
12.1.
Treatment Discontinuations
The following events are considered sufficient reasons for discontinuing a subject from the 
investigational product :
!
Adverse Event
!
Progressive Disease
!
Symptomatic deterioration (global deterioration of health status)
!
Physician decision
!
Withdrawal by subject
!
Death
!
Lost to follow-up
!
Protocol violation
!
Other (to be specified on CRF)
The reason for discontinuation of treatment should be recorded in the CRF and in the source 
documents.
The decision to discontinue a subject from treatment remains the responsibility of the treating 
physician, which will not be delayed or refused by the sponsor.  However, prior to discontinuing 
a subject, the Investigator may contact the Medical Monitor and forward appropriate supporting 
documents for review and discussion.
12.2.
Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
!
Adverse Event
!
Progressive disease
!
Withdrawal by subject
!
Death
!
Lost to follow-up
!
Protocol violation
!
Other
The reason for study discontinuation should be recorded in the CRF and in the source 
documents.
&(/*(1(35235,(7$5<,1)250$7,21
corded in th
orded in
ent
ent remain
remain
d by the sp
d by the sp
Medical Mo
Medical Mo
tion
on
idered suffi
dered suff
ntnt
sive disease
sive diseas
hdrawal by
hdrawal b
Death
Death
!
Lost t
ost t
!
P

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week. The representatives are responsible 
for obtaining your call-back information and contacting the on call Celgene/contract research 
organization (CRO) Medical Monitor, who will then contact you promptly.
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls. 
13.2.
Emergency Identification of Investigational Products
The blind must not be broken during the course of the study unless in the opinion of the 
Investigator, it is absolutely necessary to safely treat the subject. IF it is medically imperative to 
know what IP the subject is receiving, IP should be temporarily discontinued if, in the opinion of 
the Investigator, continuing IP can negatively affect the outcome of the subject’s treatment.
The decision to break the blind in emergency situations remains the responsibility of the treating 
physician, which will not be delayed or refused by the Sponsor. However, the Investigator may 
contact the Medical Monitor prior to breaking the blind to discuss unblinding, mainly in the 
interest of the subject.
The Investigator should ensure that the code is broken only in accordance with the protocol.  The 
Investigator should promptly notify the Medical Monitor of the emergency unblinding and the 
reason for breaking the blind, which should be clearly documented by the Investigator in the 
subject’s source documentation.
Emergency unblinding should only be performed by the Investigator through the IRT by using an 
emergency unblinding personal identification number (PIN), and the Investigator should call IRT 
for unblended dose information.
&(/*(1(35235,(7$5<,1)250$7,21
not be
ot b
ed on
d on
Emergency
Emergenc
esponsible
esponsible
ract researc
act resear
nly
nly b
y e used
e used
or or design
r or desig
nal Produ
nal Pro
dy
dy unless in
unless in
y
he subject. I
e subject. I
temporarily
temporari
fect the outc
ect the out
y situations 
y situations
fused by th
fused by th
reaking the
aking the
that the cod
that the cod
notify the 
notify the 
ind, which 
d, which 
mentation.
mentation.
ding s
ding shoul
hould
indi
inding pers
ng per
d dose info
dose info

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonisation (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki. The study will receive approval from an 
IRB/EC prior to commencement. The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions, 
including obligations of confidentiality of Celgene information. The Investigator should maintain 
a list of Sub-investigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of CRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by Celgene on public registry websites) is considered Celgene confidential 
information.  Only information that is previously disclosed by Celgene on a public registry 
website may be freely disclosed by the Investigator or its institution, or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment and IB information is not to be made publicly 
available (for example on the Investigator’s or their institution’s website) without express written 
approval from Celgene.  Information proposed for posting on the Investigator’s or their 
institution’s website must be submitted to Celgene for review and approval, providing at least 5 
business days for review.
At the time results of this study are made available to the public, Celgene will provide 
Investigators with a summary of the results that is written for the lay person.  The Investigator is 
responsible for sharing these results with the subject and/or their caregiver as agreed by the 
subject.
&(/*(1(35235,(7$5<,1)250$7,21
in 
authori
authorititi
i es
es
ical Practic
ical Practic
evaluate an
valuate
study
ud are a
re
y
study
study-relate
rel
ation. The I
. The
fied persons
fied person
ord of all su
rd of all su
study.  Subj
tudy.  Subj
documents.
ocuments
ber of the In
er of the I
olve querie
olve quer
ospital chart
spital cha
must ensur
must ensu
d in the pro
n the pro
y Celgene 
Celgene
y
nform
orm
f
ata ioion
reely disclo
reely disclo
ent.  Cel
nt.  Celgen
ge
for example
or example
from
om
f
Cel
Cel
m
g
utition’s web
on’s web
siness days
ness days
At
At the tim
the tim
vest
vest

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a subject and/or a subject’s legal representative 
prior to any study related procedures.
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original ICF signed and dated by the study subject and by the person 
consenting the study subject prior to the study subject’s entry into the study, must be maintained 
in the Investigator’s study files and a copy given to the study subject.  In addition, if a protocol is 
amended and it impacts on the content of the informed consent, the ICF must be revised.  Study 
subjects participating in the study when the amended protocol is implemented must be re-
consented with the revised version of the ICF.  The revised ICF signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed ICF, it is the responsibility of the Investigator to obtain such permission in 
writing from the appropriate individual.
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is 
sought. If applicable, the documents will also be submitted to the authorities in accordance with 
local legal requirements.
IP can only be supplied to an Investigator by Celgene or its authorized representative after 
documentation on all ethical and legal requirements for starting the study has been received by 
&(/*(1(35235,(7$5<,1)250$7,21
ol is
ol is
Study
Study
re-
the study
the study
Invest
nvestigato
igato
privacy
ivacy an
an
y
d
ost stringen
st stringen
necessary, 
necessa
cords relev
cords relev
iver or auth
ver or au
Invest
Inve igato
iga
st be approv
t be app
endments w
ndments 
ned before
ned before
m the IRB/E
the IRB
m
tle and ame
and 
re do not re
e do not re
poses.
poses.
nstitution
nstitution
an
and App
d App
e the st
e the
art o
art o
submitted t
ubmitted t
dates of iss
dates of iss
sought. 
ought
al

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Celgene or its authorized representative. This documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For 
example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by the IRB/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a committee member. Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC. This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:
!
Information on serious or unexpected adverse events as soon as possible; 
!
Periodic reports on the progress of the study;
!
Deviations from the protocol or anything that may involve added risk to subjects.
14.8.
Termination of the Study
Celgene reserves the right to terminate this study prematurely at any time for reasonable medical 
or administrative reasons. Any premature discontinuation  will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc).
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!
Unsatisfactory enrollment;
!
GCP noncompliance;
!
Inaccurate or incomplete data collection;
!
Falsification of records;
!
Failure to adhere to the study protocol.
&(/*(1(35235,(7$5<,1)250$7,21
otocol
ocol
aluated to
aluated to
also be rev
also be rev
and, if app
and, if app
o applies to
applie
r, if applica
r, if applic
be reviewe
e revi
nal Revie
nal Revie
vestigator m
estigator 
pected adve
pected adv
gress of the
gress of the
otocol
otoco or a
or
l
of the Stu
of the S
ht to termin
ht to term
sons. Any
ons. Any p
y
requireme
requireme
e Invest
Investiga
ig
study
tudy f
y or m
or m
f
!
Unsat
Unsati
!
G
!

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include: hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; X-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of CRFs or CD-ROM.
15.2.
Data Management
Data will be collected via CRF and entered into the clinical database per Celgene standard 
operating procedures (SOPs). This data will be electronically verified through use of 
programmed edit checks specified by the clinical team.  Discrepancies in the data will be brought 
to the attention of the clinical team, and investigational site personnel, if necessary.  Resolutions 
to these issues will be reflected in the database.  An audit trail within the system will track all 
changes made to the data.
15.3.
Record Retention
Essential documents must be retained by the Investigator according to the period of time outlined 
in the clinical trial agreement. The Investigator must retain these documents for the time period 
described above or according to local laws or requirements, whichever is longer. Essential 
documents include, but are not limited to, the following:
!
Signed informed consent documents for all subjects;
!
Subject identification code list, screening log (if applicable), and enrollment log;
!
Record of all communications between the Investigator and the IRB/EC;
!
Composition of the IRB/EC;
!
Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);
!
List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!
Copies of CRFs (if paper) and of documentation of corrections for all subjects;
!
IP accountability records;
!
Record of any body fluids or tissue samples retained;
!
All other source documents (subject records, hospital records, laboratory records, 
etc.); 
&(/*(1(35235,(7$5<,1)250$7,21
on as 
n as 
macy, and 
macy, and
elgene
elgene stan
stan
hrough use 
ugh us
es in the da
s in the d
nnel, if nece
nel, if nec
witithin the s
hin 
stigator acc
tigator acc
must retain
must reta
r requirem
r requirem
the follo
the follow
documents 
documen
code list, s
code list, 
mmu
mmunicati
nica o
of
of the IRB
e IR
f
f all co
all comm
mm
sentative(s)
sentative(s)
ist of Sub
ist of Sub
Invest
Investiga
iga
the stu
e stu
!
Co
Co
!

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements. Details of these arrangements should be 
documented. 
All study documents should be made available if required by relevant health authorities. 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.
&(/*(1(35235,(7$5<,1)250$7,21
tion of 
tion of 

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative 
for compliance with applicable government regulations with respect to current GCP and SOPs.
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  All aspects of the study are reviewed with the Investigator and the staff at a study
initiation visit and/or at an Investigator meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protocol, CRFs, procedures for obtaining informed 
consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring will 
include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  During monitoring visits, the facilities, 
investigational product storage area, CRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative in accordance with the 
Study Monitoring Plan.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the CRFs or via queries by the Investigator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs  to evaluate compliance with Good Clinical Practice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (eg, FDA, EMA, Health Canada) and 
company authorized representatives.  The Investigator should make every effort to be available 
for the audits and/or inspections.  If the Investigator is contacted by any regulatory authority 
regarding an inspection, he/she should contact Celgene immediately.
&(/*(1(35235,(7$5<,1)250$7,21
y
y, a
med 
med 
ring will
ring will
pri
priate
ate
the facilit
the facilitiei
nd all other 
d all other 
 in accorda
n acco
that i
ha s a di
a d
document
docume
r his/her sta
his/her st
ries by the 
ries by th
onsents, adh
onsents, adh
per recordin
er recordin
y-specific m
specific 
procedures
procedu
sentatives o
sentatives o
elgene SOP
lgene SOP
red to perm
red to pe
RFs and ap
RFs and a
ons by IRB
ns by IRB
rized repres
rized repre
s and/or ins
s and/or ins
an inspect
n inspect

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
17.
PUBLICATIONS
As described in Section 14.2 all protocol- and amendment-related information, with the 
exception of the information provided by Celgene on public registry websites, is considered 
Celgene confidential information and is not to be used in any publications.  Celgene protocol-
related information proposed for use in a publication must be submitted to Celgene for review 
and approval, and should not be utilized in a publication without express written approval from 
Celgene, or as described in the Clinical Trial Agreement.  
Celgene will ensure Celgene-sponsored studies are considered for publication in the scientific 
literature in a peer-reviewed journal, irrespective of the results.  At a minimum, this applies to 
results from all Phase 3 clinical studies, and any other study results of significant medical 
importance.  This also includes results relating to investigational medicines whose development 
programs have been discontinued.
Study results may also be presented at one or more medical congresses, and may be used for 
scientific exchange and teaching purposes.  Additionally, this study and its results may be 
submitted for inclusion in all appropriate health authority study registries, as well as publication 
on health authority study registry websites, as required by local health authority regulations.  
Eligibility for external authorship, as well as selection of first authorship, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data quality, participation in data analysis, participation in study steering committee 
(when applicable) and contribution to abstract, presentation and/or publication development.
&(/*(1(35235,(7$5<,1)250$7,21
tific
ific
pplies to
plies to
edical
edical
se developm
se develop
nd may
nd may b
y e
d i
d its resul
ts resul
i
ts
l
stries, as w
ries, as w
healt
alth autho
uth
t authorshi
t authorsh
ibution to p
ibution to p
, part
 participati
icipat
entation an
entation a

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
18.
REFERENCES
Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs 
BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the 
primary outcome. Br J Cancer. 2000;83(4):447-453.
Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther 
Adv Med Oncol. 2011;3(6):279-291.
Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for 
the treatment of lung cancer. Cancer Immunol Res. 2013;1(2):85-91.
Brahmer JR, Horn L, Antonia SJ, et al. Survival and long-term follow-up of the phase I trial of 
nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated 
advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;(suppl; abstr 8030).
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in 
patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for 
advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 
2006;32(8):583-587.
Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced 
non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1999;17(7):2081-2085.
Edge SB, Byrd DR, Compton CC, et al. AJCC cancer Staging Manual. 7th Ed. Springer, 2009.
Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
revised RECIST guideline (version 1.1). Eur J Cancer. 45(2):228-247.
ESMO Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. Available at: 
www.esmo.org/Guidelines/Lung-Cancer/Metastatic-Non-Small-Cell-Lung-Cancer. Accessed 
11Feb2015.
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus 
vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated 
with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18(12):2354-2362.
Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic 
syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 
2011;29(18):2521-2527.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung 
cancer. N Engl J Med. 2015;372:2018-2028.
Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of pembrolizumab in 
previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract]. In: 
Proceedings of the 2014 ASCO Annual Meeting; 2014 May 30-Jun 3; Chicago, IL. J Clin Oncol.
32:5s, 2014 (suppl; abstr 8020).
Gilotrif [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. 
Revised April 2014.
&(/*(1(35235,(7$5<,1)250$7,21
for 
or 
f
se I tri
se I trialal of
o
l
sly treated 
sly treated 
str 8030).
r 8030).
L1 antibod
L1 antibod
.
d line chem
d line che
ed trials.
ed tr
C
s second
second-li
ol.l. 1999;17
 1999;1
ncer Stagin
ncer Stagi
ew respons
ew respons
ur J Cancer
r J Cance
etastatic N
tastatic N
ancer/Meta
ncer/Met
r RN, et al.
r RN, et al
in pat
in patieients
ng chemot
ng chemot
Gore SD, C
Gore SD, 
onic myelo
onic myelo
:2521
:2521-2527
-2527
B, Ri
Rizvi
zvi NA
N
i
r. N Engl
r. N Engl J
Garon EB, L
Garon EB, 
previousl
previousl
rocee
rocee

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalance Worldwide in 2012. 
Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 11Feb2015
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus 
docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J 
Clin Oncol. 2004;22(15):1589-1597.
Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol 
Ther. 2014;96(2):214-223.
Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in 
patients with refractory advanced non small cell lung cancer. Cancer Discov. 2011;1(7):598-607.
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell 
lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818.
Lang-Lazdunski L. Surgery for nonsmall cell lung cancer. Eur Respir Rev. 2013;22(129):382-
404.
Miranda RB, Jones PA. DNA methylation: the nuts and volts of repression. J Cell Physiol. 
2007;213(2):384-390.
NCCN Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.4.2014.  Available at: 
http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 11Feb2015.
Perol M, Ciuleanu TE, Arrieta O. REVEL: A randomized, double-blind, phase III study of 
docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the 
second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease 
progression after one prior platinum-based therapy. J Clin Oncol. 2014; 32 (5s): suppl; abstr 
LBA8006.
Peterson P, Park K, Fossella FV, et al. Is pemetrexed more effective in adenocarcinoma and 
large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III 
trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung 
cancer (NSCLC): P2-328 [abstract]. In: 12th World Conference on Lung Cancer. J of Thoracic 
Oncol 2007;2(8 suppl 4):S851.
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus 
placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 
3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2): 143-155.
Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line 
chemotherapy for non small cell lung cancer. Lung Cancer. 2000;29(1):67-73.
Shaw AT, Kimm D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-
positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best 
supportive care in patients with non-small-cell lung cancer previously treated with platinum-
based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-
cell lung cancer. N Engl J Med. 2005;353(2):123-132.
&(/*(1(35235,(7$5<,1)250$7,21
98
98-607.
607.
mall
mall-cell
cell
809
09-1818.
-1818.
13;22
3;22(129)
(129
sioion. J Cell
n. J Ce
Cancer v.4
Cancer v.4
f.f Accessed
Accesse
d, double-
, double b
B) versus D
B) versus 
ng cancer (
ng cancer 
apy. 
py. J Clin O
J Clin O
pemetrexe
pemetrexe
us cell carci
us cell carc
previously 
reviously
act]. In: 12t
act]. In: 12
1.1.
mgaard A, 
mgaard
h previ
prev
h
ous
ous
ndomised c
mised c
itte JJ, Berg
tte JJ, Be
py for non s
py for non 
T, Kimm D
T, Kimm D
ve
ve lung ca
lung c
Shepherd FA
hepherd F
supportiv
upportiv
sed
sed

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Speicher MR, Petersen S, Uhrig S, et al. Analysis of chromosomal alterations in non-small cell 
lung cancer by multiplex-FISH, comparative genomic hybridization, and multicolor bar coding. 
Lab Invest. 2000;80(7):1031-1041.
Tarceva [package insert]. OSI Pharmaceuticals, LLC, Northbrook, IL, USA an affiliate of 
Astellas Pharma US, Inc., 2012.
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated 
patients with refractory advanced non-small-cell lung cancer: results from a randomised, 
placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 
2005;366(9496):1527-1537.
Topalian SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J 
Med. 2012;366(26):2443-2454.
Topaloglu, O, Hoque, MO, Tokumaru, Y, et al. Detection of promoter hypermethylation of 
multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer 
Res. 2004;10(7):2284–2288.
Xalkori [package insert]. Pfizer Labs, New York, NY, USA, revised Aug, 2011.
Zeng L, Jarrett C, Brown K, et al. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a 
role in the anti-tumorigenic effects of 5-Aza-2’-deoxycytidine (AZA) in breast cancer cells. Exp 
Cell Res. 2013;319(14):2282-2295.
&(/*(1(35235,(7$5<,1)250$7,21
N Engl J 
N Engl J 
thylat
thylatioion o
n
g cancer. Cl
g cancer. C
Aug,
Aug, 2011.
2011.
ing protein
g protein
(AZA) in b
(AZA) 

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
19.
APPENDICES
19.1.
Appendix A: RECIST 1.1
The following information is extracted/summarized from Eisenhauer, 2009, New response
evaluation criteria in solid tumors:  Revised RECIST guideline (version 1.1). Please refer to the 
primary reference for further information.
19.1.1.
Definitions
At screening, tumor lesions/lymph nodes will be categorized as measurable or non-measurable.
19.1.1.1.
Measurable Disease
Tumor Lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
!
10 mm by CT scan (CT scan slice thickness no greater than 5 mm)
!
10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non-measurable)
!
20 mm by chest X-ray
Malignant Lymph Nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will 
be measured and followed.
19.1.2.
Tumor Response Evaluation
19.1.2.1.
Target Lesions
When more than one measurable tumor lesion is present at baseline all lesions up to a maximum 
of 5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements. Note that pathological nodes must meet the measurable 
criterion of a short axis of ≥ 15 mm by CT scan and only the short axis of these nodes will 
contribute to the baseline sum. All other pathological nodes (those with short axis ≥ 10 mm but 
< 15 mm) should be considered non-target lesions. Nodes that have a short axis < 10 mm are 
considered non-pathological and should not be recorded or followed. At baseline, the sum of the 
target lesions (longest diameter of tumor lesions plus short axis of lymph nodes:  overall 
maximum of 5) is to be recorded.
After baseline, a value should be provided on the CRF for all identified target lesions for each 
assessment, even if very small. If extremely small and faint lesions cannot be accurately 
measured but are deemed to be present, a default value of 5 mm may be used. If lesions are too 
small to measure and indeed are believed to be absent, a default value of 0 mm may be used.
&(/*(1(35235,(7$5<,1)250$7,21
surable.
surable.
est di
est d amete
mete
n 5 mm)
n 5 mm)
which cann
which cann
measurable)
measura
cally enlarg
cally enlarg
by
by CT scan
CT sca
y
aseline and
seline and
n
le tumor le
e tumor le
imum of 2
imum of
rget l
rget lesi
es ons
cted on the
ted on the
l invo
l involved 
lved 
peated meas
eated mea
short axis o
hort axis 
to the base
o the base
m) should b
m) should 
idered non
dered non
arget lesio
arget lesion
maximum
maximum
ter

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
19.1.2.2.
Non-target Lesions
All non-measurable lesions (or sites of disease) plus any measurable lesions over and above 
those listed as target lesions are considered non-target lesions. Measurements are not required 
but these lesions should be noted at baseline and should be followed as “present,” “absent,” or 
“unequivocal progression.”
19.1.2.3.
Response Criteria
Target and non-target lesions are evaluated for response separately, and then the tumor burden as 
a whole is evaluated as the overall response.
19.1.2.3.1. Target Lesion Response
Target lesions will be assessed as follows:
!
Complete Response (CR).  Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to < 10 
mm.
!
Partial Response (PR).  At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters.
!
Progressive Disease (PD).  At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum 
if that is the smallest on study). In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 5 mm. (Note:  the appearance 
of one or more new lesions is also considered progression).
!
Stable Disease (SD).  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of diameters while on 
study.
19.1.2.3.2. Non-target Lesion Response
Non-target lesions will be assessed as follows:
!
Complete Response (CR).  Disappearance of all non-target lesions and normalisation 
of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm 
short axis).
!
Non-CR/Non-PD.  Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.
!
Progressive Disease (PD).  Unequivocal progression (see comments below) of 
existing non-target lesions. (Note: the appearance of one or more new lesions is also 
considered progression).
When the Subject Also Has Measurable Disease:  In this setting, to achieve “unequivocal 
progression” on the basis of the non-target disease, there must be an overall level of substantial 
worsening in non-target disease such that, even in presence of SD or PR in target disease, the 
overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest 
“increase” in the size of one or more non-target lesions is usually not sufficient to quality for 
&(/*(1(35235,(7$5<,1)250$7,21
as 
as 
ny patho
y pathololog
n in short a
in short a
um
u
of
of
m
diam
dia
f
rs.
se in the su
se in the su
on study
n study (th
(th
y
to the rel
to the rela
ase of at le
ase of at le
nsidered pr
nsidered pr
fficient shri
fficient shr
king as refe
king as refe
Response
Response
sessed as fo
sessed as f
sponse (CR
sponse (C
marker l
arker eve
ev
xis).
xis).
n-CR/Non
CR/Non
maintena
maintenanc
n
!
Progre
rogre
exis
exis
When t
When 

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
unequivocal progression status. The designation of overall progression solely on the basis of 
change in non-target disease in the face of SD or PR of target disease will therefore be extremely 
rare.
When the Subject Has Only Non-measurable Disease:  This circumstance arises in some 
Phase 3 trials when it is not a criterion of study entry to have measurable disease. The same 
general concepts apply here as noted above; however, in this instance there is no measurable 
disease assessment to factor into the interpretation of an increase in non-measurable disease 
burden. Because worsening in non-target disease cannot be easily quantified (by definition:  if all 
lesions are truly non-measurable) a useful test that can be applied when assessing subjects for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease: ie, an increase in tumor burden representing an 
additional 73% increase in “volume” (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large,” 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as “sufficient to require a change in therapy.” If “unequivocal progression” is seen, the 
subject should be considered to have had overall PD at that point. While it would be ideal to 
have objective criteria to apply to non-measurable disease, the very nature of that disease makes 
it impossible to do so: therefore, the increase must be substantial.
19.1.2.3.3. Overall Response
Overall response should be assessed according to Table 9 for subjects with target lesions, and
Table 10 for subjects with only non-target lesions.
Table 9:
Time Point Response: Subjects With Target (± Non-target) Disease
Target Lesions 
Response
Non-target Lesion Response
New Lesions
Overall Response
CR
CR
No
CR
CR
Non-CR/ non-PD
No
PR
CR
Not evaluated
No
PR
PR
Non-PD or not all evaluated
No
PR
SD1
Non-PD or not all evaluated
No
SD
Not all evaluated
Non-PD
No
NE
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
CR = complete response, NE = inevaluable, PD = progressive disease, PR = partial response, SD = stable disease
&(/*(1(35235,(7$5<,1)250$7,21
all
all
or r 
he
he
uld be
ld be
esent
esenting an
ng an
meter in a
meter in a
trace” to “l
race” to “
be describe
e describe
progressio
progress
hile it wou
ile it wou
ry nature of
y nature o
al.
al.
lele 9 fo
for su
r su
ts With Ta
ts With Ta
Lesion Resp
sion Resp
5,
23
R/ non
R/ non-PD
PD
52
ot evaluated
evaluated
35
Non
Non-PD 
D
( 3
1(
Non
Non
1(
1(
1(
1(
d
N
(1
*(
/*
ny
(/
&(
CR = comp
CR = comp

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 10:
Time Point Response: Subjects With Non-target Disease Only
Non-target Lesion Response
New Lesions
Overall Response
CR
No
CR
Non-CR/ non-PD
No
Non-CR/non-PD1)
a
Not all evaluated
No
NE
Unequivocal PD
Yes or No
PD
Any
Yes
PD
CR = complete response, PD = progressive disease, NE =  inevaluable
a “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since SD is increasingly used as 
endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is 
not advised.
19.1.2.4.
Symptomatic Deterioration
Subjects with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
‘symptomatic deterioration’. Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response: it is a reason for stopping study therapy. The objective response status of 
such subjects is to be determined by evaluation of target and non-target disease.
&(/*(1(35235,(7$5<,1)250$7,21
$7
$7
$7
0$7
$
used as 
ed as
e measured i
e measured i
uatioion of tre
n of
d be reporte
be report
ment objec
ment objec
tion is not 
on is 
 The objec
The objec
and non
nd non-tar

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
19.2.
Appendix B: irRECIST
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST
&(
pri
prietet
0$7,21
e Corpora
e Corpora
21

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
pri
prietet
7,21
e Corpora
e Corpora
21

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
95
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet
(/

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
96
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(
pri
prietet
7,21
e Corpora
e Corpora
21

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
97
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(
pri
prietet
7,21
e Corpora
e Corpora
21

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
98
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
99
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
19.3.
Appendix C: Table of Abbreviations
Table 12:
Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term
Explanation
AE
Adverse event
AIM
Azacitidine-induced immune
AJCC
American Joint Committee on Cancer
ALT
Alanine aminotransferase (SGPT)
ALK 
Anaplastic lymphoma kinase
AML
Acute myeloid leukemia
ANC
Absolute neutrophil count
aPTT
Activated partial thromboplastin time
ASCO
American Society of Clinical Oncology
AST
Aspartate aminotransferase (SGOT)
AUC
Area under the concentration-time curve
AZA
Azacitidine
β-hCG
Beta-subunit of human chorionic gonadotropin
BCG
Bacillus Calmette-Guerin
BLQ
Below the limit of quantitation
BSC
Best supportive care
BUN
Blood urea nitrogen
CBC
Complete blood count
CI
Confidence interval
CL/F
Apparent total body clearance
Cmax
Maximum plasma concentration of drug
CMMoL
Chronic myelomonocytic leukemia
CNS
Central nervous system
CR
Complete response
CRA
Clinical research associate
CRO
Contract research organization
CRF
Case report form
CSR
Clinical Study Report
CT
Computed tomography
&
F
&(
CRO
CR
&(/*(1(35235,(7$5<,1)250$7,21
$7
$7
$7
$7
0$
50
25
2
1)
,1
< ,
curve
urve
5<
$5
horionic gon
horionic gon
7$
uerin
rin
(7
of quantitati
of quantitati
5,(
tive care
ive car
35
urea nitrogen
a nitrogen
23
mplete bloo
mplete blo
52
Confidenc
Confidenc
35
(
Appar
Appar
( 3
1(
M
1(
1(
1(
(1
*(
/*
RA
(/
&(
&

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
100
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 12:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
CTCAE
Common Terminology Criteria for Adverse Events
DCR
Disease control rate
DIC
Disseminated Intravascular Coagulation
DILI
Drug-induced liver injury
DKA
Diabetic ketoacidosis
DLT
Dose-limiting toxicity
DNA
Deoxyribonucleic acid
DNMT1
DNA methyltransferase-1
DNMTi
DNA methyltransferase inhibitor
DMC
Data Monitoring Committee
EBUS
Endobronchial ultrasound
EC
Ethics Committee
ECI
Events of clinical interest
ECG
Electrocardiogram
ECOG
Eastern Cooperative Oncology Group
eCRF
Electronic case report form
EEA
European Economic Area
EGFR
Epidermal growth factor receptor
ESMO
European Society for Medical Oncology
EOT
End of treatment
EU
European Union
FFPE
Formalin fixed paraffin embedded
FAB
French American British
FDA
Food and Drug Administration
GCP
Good Clinical Practice
G-CSF
Granulocyte colony-stimulating factor
GM-CSF
Granulocyte macrophage colony-stimulating factor
GI
Gastrointestinal
GITR
Glucocorticoid-induced tumor necrosis factor receptor
HBV
Hepatitis B virus
&(
GM
GM
&(/*(1(3
Europe
Europ
35235,(7$5<,1)250$7,21
7
$7
$7
$7
$
0
5
2
)2
1
< ,
5<
$5
7$
Oncology G
ncology G
(7
eport form
port form
5,(
onomic Are
nomic Ar
35
al growth fa
growth f
23
opean Socie
pean Socie
52
End of trea
End of trea
35
3
(
Fo
Fo
(
1(
(1
*(
/*
CSF
SF
(/
-CSF
CSF
&(
&

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
101
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 12:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
HBcAb
Hepatitis B core antibody
HBeAb
Hepatitis B e antibody
HBeAg
Hepatitis B e antigen
HBsAg
Hepatitis B surface antigen
HBsAb
Hepatitis B surface antibody
HCl
Hydrochloride
HCV
Hepatitis C virus
HCVAb
Hepatitis C virus antibody
HDAC
Histone deacetylase
HIV
Human immunodeficiency virus
HR
Hazard ratio
HUS
Haemolytic Uraemic Syndrome
ICF
Informed consent form
IB
Investigator’s Brochure
ICH
International Conference on Harmonisation
iDMC
Independent Data Monitoring Committee
IDO
Indoleamine 2,3-dioxygenase
ILD
Interstitial lung disease
IND
Investigational New Drug
INR
International normalized ratio
IP
Investigational Product
IRB
Institutional Review Board
irAEs
Immune-related adverse events
irDCR
Immune-related disease control rate
irPFS
Immune-related progression-free survival
irRC
Immune-related response criteria
irRECIST
Immune-related Response Evaluation Criteria in Solid Tumors
irORR
Immune-related overall response rate
IRT
Interactive response technology
ITT
Intent-to-treat
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
25
)2
1)
,1
5<
$5
7$
ce on Harm
e on Harm
(7
Monit
onitoring 
oring 
,(
,3,3-dioxygen
dioxyg
5
l lung disea
lung dise
23
tigational N
tigational N
2
nternational
nternatio
5
Investig
vest
3
(
Inst
Ins
(
1(
1(
1(
1(
(1
*(
/*
rRECIST
rRECIST
&(
ORR
ORR
&

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
102
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 12:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
ITP
Idiopathic (or immune) Thrombocytopenia Purpura
IV
Intravenous
LDH
Lactate dehydrogenase
LFT
Liver function test
mAb
Monoclonal antibody
MDS
Myelodysplastic syndrome
MM
Multiple myeloma
MedDRA
Medical Dictionary for Regulatory Activities
MRI
Magnetic resonance imaging
MTD
Maximum tolerated dose
NCCN
National Comprehensive Cancer Network
NCI
National Cancer Institute
NSCLC
Non-small cell lung cancer
NYHA
New York Heart Association
ORR
Overall response rate
OS
Overall survival
PD
Pharmacodynamics
PD
Progressive disease
PD-1
Programmed cell death protein-1
PD-L1
Programmed death-ligand 1
PE
Physical examination
PFS
Progression-free survival
PK
Pharmacokinetics
PR
Partial response
PT
Prothrombin time
PTT
Partial thromboplastin time
QD
Once daily
RBC
Red blood cell count
RCC
Renal cell carcinoma
RECIST
Response Evaluation Criteria in Solid Tumors
&
BC
BC
&(
QD
QD
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
25
)2
1)
k
,1
5<
$5
n
7$
(7
,(
amics
amics
5
ve disease
ve disease
23
rammed cell
ammed cel
2
Programmed
Programm
5
Physical
ysic
3
(
Prog
Pro
(
1(
1(
1(
1(
(1
*(
/*
&(
&

('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
103
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 12:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
RNA
Ribonucleic acid
SAE
Serious adverse event
SAP
Statistical analysis plan
SC
Steering Committee
SC
Subcutaneous
SD
Stable disease
SGOT
Serum glutamic oxaloacetic transaminase 
SGPT
Serum glutamic pyruvic transaminase
SOP
Standard operating procedure
SUSAR
Suspected unexpected serious adverse reaction
TEAE
Treatment-emergent adverse event
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TKI
Tyrosine kinase inhibitor
TIL
Tumor-infiltrating lymphocyte
Tmax
Time to maximum concentration
TTP
Thrombotic Thrombocytopenic Purpura
t1/2
Terminal half-life
ULN
Upper limit of normal
US
United States 
Vz/F
Apparent volume of distribution
WBC
White blood cell count
WHO
World Health Organization
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$
0
5
2
)2
ion
ion
1
< ,
5<
$5
7$
mphocyte
mphocyte
(7
m concentra
m concentr
5,(
Thrombocyt
hrombocy
35
 half
a -f life
life
23
per limit of n
er limit of n
52
United Stat
United Sta
35
Appare
Appar
3
(
W
(
1(
(1
*(1

('06'RF1XPEHU
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
8VHU1DPH

7LWOH

'DWH0RQGD\'HFHPEHU30(DVWHUQ'D\OLJKW7LPH
0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\
                                                
&(/*(1(35235,(7$5<,1)250$7,21
H